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ABSTRACT 
The current view of signal transduction is that external stimuli trigger a series 
of cytosolic signaling events, which lead to the translocation of transcription factors, 
and changes in gene expression, which are dependent on the epigenetic landscape. 
Here, we discuss a paradoxical signaling paradigm in which a crucial chromatin 
modifier, Polycomb Repressive Complex 2 (PRC2), directly regulates receptor-
proximal signaling. PRC2 catalyzes di/tri-methylation of histone 3 lysine 27 
(H3K27me3), which correlates with transcriptional repression. While lysine 
methylation has largely been studied in the context of histone modification and 
epigenetic regulation, its role in the context of receptor-mediated signaling has rarely 
been described. In this study, we demonstrate that lysine methylation of cytosolic 
substrates by a cytosolic PRC2 complex plays an essential role in TCR-mediated T 
cell activation, independently from its nuclear function. Genetic ablation of essential 
PRC2 components in T cells had no effect on T cell development, loss of H3K27me3 
or corresponding changes in gene expression. The resulting PRC2 deficient naïve T 
cells provided us with a good tool to study the signaling role of PRC2 in T cell 
	  	  
activation, without an altered epigenetic landscape. These PRC2-deficient T cells fail 
to proliferate upon TCR stimulation in vitro and in vivo and PRC2-deficient T cells 
have a specific defect in TCR-induced Erk phosphorylation. Pharmacological 
inhibition of PRC2 further substantiated that PRC2 directly controls TCR signaling 
and the methyltransferase activity of PRC2 is required for TCR-induced Erk 
phosphorylation. To understand the mechanism(s) by which PRC2 controls TCR 
signaling, we examined the complex composition and identified cytosolic substrates of 
Ezh2. We found that cytosolic PRC2 (cPRC2) contains the core components of the 
nuclear PRC2 complex, indicating that its methyltransferase activity is present. 
Additionally we found that cPRC2 is associated with the TCR signaling components 
Vav1 and Nck1. We predicted Nck1 in silico as a PRC2 substrate by screening for 
target consensus-sequences among Vav1-interacting proteins. We show that Nck1 is 
methylated in vivo and Ezh2 is responsible for methylation of lysine 64 in Nck1 in 
vitro. In addition to Nck1, we also found Ezh2 is self-methylated, suggesting that 
cPRC2 may assemble a signaling complex through the methylation of several sites 
within the complex. This possibility was supported by data showing altered 
interactomes of Nck and Ezh2 upon inhibition of Ezh2 enzymatic activity. In 
summary, this study sheds light on an underappreciated role for lysine methylation of 
non-histone substrate by PRC2 in receptor-mediated signaling.  
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CHAPTER 1: INTRODUCTION 
1.1 Signaling through T cell receptor  
T cells are essential cellular components of the immune system that play an 
important role in protecting the body from pathogens. They function by recognizing 
antigens through the T cell receptor (TCR) and along with co-receptors, they form a 
TCR signaling complex. These receptors bind to short peptides of 8-10 (for class I) or 
14-20 (for class II) amino acids in length in the context of the major histocompatibility 
complex (MHC) that is present in the antigen presenting cells (APCs). T cells express 
unique TCRs after rearrangements of their germ-line encoded TCR-locus, which 
creates diversity allowing them to recognize a vast number of different antigens. Each 
T cell recognizes only a small number of antigens with their TCR and this feature 
creates specificity in their immune response.  
A series of signaling events is initiated upon binding of the TCR to the 
peptide-MHC complex. The intracellular domains of the TCR undergo a 
conformational change that allows the Src family kinase, Lck, which is associated 
with the co-receptors CD4/CD8, to phosphorylate the TCR (Barber et al., 1989). The 
TCR contains ten Immunoreceptor Tyrosine-based Activation Motifs (ITAMs), whose 
tyrosine residues are phosphorylated by Lck. The phosphorylation of the ITAMs 
recruits the Spleen Tyrosine Kinase (Syk) kinase family member, Zap70 (Zeta-Chain 
associated protein Kinase 70kDa) (Chan et al., 1991; Chan et al., 1992). Zap70 gets 
activated through phosphorylation by Lck and in turn phosphorylates the integral 
membrane adaptor protein Linker for Activation of T-cells (LAT), which recruits 
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signaling molecules such as GRB2 related adaptor protein downstream of Shc 
(GADS), Inducible T-cell kinase (Itk), SH2 domain-containing leukocyte protein of 76 
kDa (Slp76) and Phospholipase Cγ1 (PLCγ1) (Bunnell et al., 2000; Liu et al., 1999; 
Weiss et al., 1991; Zhang et al., 1998). The phosphorylation of Slp76, a scaffold 
protein that contains phospho-tyrosines, promotes its binding to Non-catalytic region 
of tyrosine kinase (Nck) and Vav (Bubeck Wardenburg et al., 1998; Tuosto et al., 
1996; Wu et al., 1996). Activation of PLCγ1 by Itk results in hydrolysis of 
phosphatidylinositol 4,5-biphosphate (PIP2) into inositol 1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG), which activate downstream signaling pathways (Secrist et al., 
1991). 
 IP3 induces Ca2+ release from the endoplasmic reticulum (ER), followed by 
further influx of extracellular Ca2+ through calcium release-activated channels 
(CRAC) (Fasolato et al., 1993). This process enables Ca2+-bound calmodulin to 
activate calcineurin to de-phosphorylate nuclear factor of activated T-cells (NFAT), 
which then translocates into the nucleus (Clipstone and Crabtree, 1992; Hogan et al., 
2003; Shaw et al., 1988).  
DAG, produced from the hydrolysis of PIP2, recruits and activates Ras guanyl 
nucleotide-releasing protein (RasGRP) and protein kinase C (PKC) (Downward et al., 
1990; Ebinu et al., 1998). RasGRP converts Ras-GDP into Ras-GTP, which binds to 
Raf1. Activated Raf1 phosphorylates mitogen-activated protein kinase kinase1/2 
(Mek1/2) (Huang et al., 1993). Activated Mek1/2 phosphorylates extracellular-signal 
regulated kinase1/2 (Erk1/2), whose translocation induces phosphorylation of many 
downstream effectors such as early growth response 1 (Egr1), ETS domain-containing 
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protein (Elk), mitogen- and stress-activated protein kinase (Msk) and ribosomal S6 
kinase (Rsk) (Anjum and Blenis, 2008; Deak et al., 1998; Hodge et al., 1998; Seger et 
al., 1992; Yang et al., 1999). Among the targets of Erk are kinases that activate 
transcription factors, which is why Erk phosphorylation has such a large impact on 
gene expression downstream of the signal transduction cascade. Chief among them is 
the DAG bound PKCθ, which activates the mitogen-activated protein kinase  (MAPK) 
pathway and the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
kB) pathway (Baier-Bitterlich et al., 1996; Bi et al., 2001; Kishimoto et al., 1980; 
Monks et al., 1997).  
Collectively, several transcription factors are activated downstream of the TCR 
and induce transcriptional programs including the binding of activator protein 1 (AP-
1) (Fos/Jun), NF-kB, NFAT and Elk that bind to the promoter of the IL-2 gene, a 
hallmark of T cell activation (Jain et al., 1995). In short, the TCR signaling pathway 
represents a general receptor-mediated signaling mechanism (Figure 1.1). First, a 
ligand, the peptide-MHC complex, binds to the TCR. Second, the binding of 
TCR:pMHC results in the phosphorylation of tyrosine-residues in intracellular tail of 
the receptor. Third, recruitment of adaptors and enzymes such as kinases and GTPases 
to the receptor are involved in the formation of signaling clusters, where downstream 
molecules are sequentially activated. Lastly, downstream signaling intermediates 
translocate/activate transcription factors to induce transcriptional changes. This last 
step is usually subject to further modulation by chromatin modifications. 
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Figure 1.1. TCR-dependent signaling pathway TCR signaling cascades are initiated 
by ligation of TCR:pMHC along with CD28:B7. These receptor:ligand interactions 
recruit adaptor molecules to the cytoplasmic tails of the receptors. Post-translational 
modifying enzymes such as kinases are bound to adaptors, in turn and activate down 
stream signaling molecules. Eventually, this cascade activates transcription factors, 
which translocate into the nucleus to promotion transcription. Additionally, chromatin 
modifying enzymes regulate the transcription of genes.  
 
1.2 Post-Translational modification and histone code hypothesis 
Post-translational modifications (PTMs) are key regulators that transduce 
signals within a cell. The covalent modification of proteins by a phosphate group, a 
methyl group, an acetyl group, poly-ubiquitin and so on, can change their 
conformation, which exposes them to effector molecules or enable interactions with 
other proteins. These modifications are thought to be highly dynamic as both 
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facilitating enzymes and reverting enzymes already exist and their activities are often 
signal dependent. 
In the past decade, post-translational modifications of histone proteins have 
garnered a lot of attention after Allis, Strahl and Jenuwein postulated the histone code 
hypothesis (Jenuwein and Allis, 2001; Strahl and Allis, 2000). Histones serve as 
scaffolds to package DNA into nucleosomes, which can be further folded into higher 
structures. According to the histone code hypothesis, specific covalent modifications 
of the N-terminal tails of histones can regulate transcriptional outcomes. For example, 
tri-methylation of histone 3 at lysine 27 (H3K27me3) is highly correlated with 
transcriptional silencing whereas tri-methylation of histone 3 at lysine 4 (H3K4me3) is 
associated with active transcription (Barski et al., 2007; Cao et al., 2002a; Strahl et al., 
1999).  
In general there are three classes of proteins described that establish and 
interact with the histone code. The first class is composed of “writers,” which add 
covalent modifications to histone tails. These modifications include lysine/arginine 
methylation, lysine acetylation, lysine ubiquitination, serine/threonine phosphorylation 
and lysine sumoylation (Kouzarides, 2007). The second class is comprised of 
“erasers,” which remove the covalent modifications on histone tails such as 
demethylases and phosphatases. The discovery of erasers indicated that histone 
modifications are not static but dynamic. However, how these processes are regulated 
is still under active investigation. The last class consists of “readers,” which recognize 
specific PTMs on histones. Examples of such proteins are PHD finger containing 
proteins or chromo-domain containing proteins that bind to methyl-lysines and bromo-
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domain containing proteins that interact with acetyl-lysines. Binding of “readers” 
controls transcriptional events such as heterochromatin formation as in the case of the 
chromo-domain protein HP-1α and transcriptional elongation mediated by the Brd4/p-
TEFb complex (Eissenberg et al., 1992; Yang et al., 2005). The coordination of post-
translational histone tail modifications and protein-protein interactions results in the 
regulation of gene transcription.  
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Figure 1.2. Histone code hypothesis Chromatin fibers are made of a bundle of 
nucleosomes, which consists of DNA wrapped around histone proteins (Kornberg, 
1974). Histones serve as building blocks to make high order structures (Upper). 
Histone proteins contain an unstructured tails in its N-terminus, where various post-
translational modifications can be added (Middle). Several lysine, arginine residues 
were identified to be methylated. Acetylation of lysine and serine/threonine 
phosphorylation also occurs. Additionally, H2A proteins were shown to be 
ubiquitinated. The histone code hypothesis proposes that certain modifications on 
specific amino acid residues of histone tails are associated with transcriptional activity 
by regulating structural features of chromatin (Bottom). 
 
1.3 Lysine methylation and protein lysine methyltransferases (PKMT) 
Lysine methylation has been extensively studied in the context of histone 
modifications. However, the initial discovery of lysine methylation was made in a 
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report describing the existence of the novel amino acid, ε-N-metyl-lysine, found in 
salmonella flagellar protein in 1959 (Ambler and Rees, 1959). The first observation on 
the methylation of lysines in histones was described five years later by Murray 
(Murray, 1964). Despite the fact that lysine methylation was initially discovered in a 
non-histone protein the biological relevance of lysine methylation has been 
extensively studied in the context of its function as an epigenetic mark. In recent 
years, the field of epigenetics has become an important area of intensive research that 
applies to many biological processes. Of particular interest is the role of epigenetic 
mechanisms in regulating cell identity by modulating the transcriptional output. 
Recently, several studies have implicated that lysine methylation of non-
histone substrates also plays a crucial role in transcription. The two best-known 
examples are lysine methylation of the NF-κB subunit RelA and p53. Lysine 310 of 
RelA (RelA K310me) can be methylated by SETD6 (Levy et al., 2011a) and this 
methylation enables GLP to bind to RelA; therefore, GLP-mediated H3K9me2 
deposition results in gene silencing at NF-κB target loci. Interestingly, RelA K310me 
and S311 phosphorylation are mutually exclusive and signal-induced RelA 
phosphorylation displaces GLP from NF-κB targets. This 
methylation/phosphorylation switch is also found in H3K9me2/me3 and S10 
phosphorylation (Fischle et al., 2005; Hirota et al., 2005), indicating that lysine 
methylation of non-histone substrates follows the principles observed in histone lysine 
methylation to some degree. There are several lysine residues on p53 that can be 
methylated. SET7/9-mediated p53 K372me1 increases promoter occupancy of p53 by 
enhancing the stability of p53 in the nucleus (Chuikov et al., 2004). An adjacent lysine 
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K372 was shown to be mono-methylated by Smyd2, which results in the abrogation of 
p53 transcriptional activity (Huang et al., 2006). Huang et al. showed that K372me1 
inhibited K370me1, suggesting a possible crosstalk between two lysine methylations. 
One important aspect a p53 methylation is that it seems to be dynamically regulated. 
Lysine specific demethylase 1 (LSD1) was shown to remove a methyl group from p53 
K372me2 that binds to its transcriptional co-activator 53BP1 (Huang et al., 2007). 
Upon demethylation of p53, binding to 53BP1 is lost and transcriptional activity 
diminished. Additional transcription factors were found to have methyl-lysines and the 
methylations of these residues are also involved in transcriptional regulation. 
In addition to transcription, lysine methylation of non-histone substrates has 
recently been reported to be essential for signaling. Smyd3-mediated MAP3K2 
methylation increases Erk1/2 phosphorylation in a Ras-driven cancer model (Mazur et 
al., 2014). The MAP3K2 K260 methylation prevents its binding to PP2A; therefore, 
the MAPK pathway was overactive in Smyd3 overexpressing cancer cells. In addition, 
VEGFR-2 methylation was shown to be required for tyrosine phosphorylation of 
VEGFR-2 (Hartsough et al., 2013). Although the studies mentioned above suggest that 
lysine methylation plays a role in signaling pathways, it is yet to be determined 
whether lysine methylation can be dynamically regulated in signal transduction and 
termination, as shown in phosphorylation-dependent signaling pathways.  
The group of enzymes that mediate lysine methylation are called protein lysine 
methyltransferases (PKMTs). Since most methyltransferases were found to methylate 
histone proteins, they were designated as histone lysine methyltransferases (HKMTs). 
The human genome encodes more than 50 PKMTs. Most of them belong to the SET 
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(Su(var)3-9, Enhancer of zeste, Trithorax)-domain protein superfamily, with the 
exception of  DOT1L, which is a non-SET domain lysine methyltransferase (Dillon et 
al., 2005). SET domains are comprised of around 130 amino acids and bind the 
universal methyl-donor and co-factor S-adenosyl methionine (SAM) which acts as a 
substrate for catalysis. These enzymes transfer one, two or three methyl groups 
donated from SAM to ε-N-lysine residues of their substrates. Many PKMTs were 
identified as “writers” of the histone code by genetic and biochemical approaches. As 
such, G9a, GLP, Suv39h1, Suv39h2 and ESET are responsible for the deposition of 
H3K9me3 marks and MLLs, SET1a, SET1b and SET7/9 were found to be responsible 
for the methylation of H3K4. In addition, NSD proteins were reported to be the 
enzymes for H3K36 methylation (Wagner and Carpenter, 2012). However, in the case 
of the H3K27me3 mark, there are only two enzymes capable of this modification, 
Ezh2 and its homolog Ezh1. 
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Figure 1.3. A phylogenetic tree of lysine methyltransferases and lysine 
methylation A. Phylogenetic tree of lysine methyltransferases encoded in the human 
genome. Ezh2 and its closely related homolog Ezh1 are the only known enzymes for 
H3K27me3 (Richon et al., 2011). B. Chemical reaction of lysine methylation. Up to 
three methyl groups donated by S-adenosyl methionine (SAM) can be added to ε-
amino group lysine by protein lysine methyltransferase (PKMT). S-adenosyl 
homosystein (SAH) is made as byproduct.  
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1.4 Transcriptional Repression by Polycomb Repressive Complex 2 
Ezh1 and Ezh2 are the enzymatic subunits of the polycomb repressive complex 
2 (PRC2). PRC2 is a multi-protein complex which consists of at least 3 core 
components: Ezh1 or Ezh2, Eed and Suz12. These components are functionally 
necessary for PRC2 methyltransferase activity in vivo and in vitro (Faust et al., 1995; 
O'Carroll et al., 2001; Pasini et al., 2004). Initial purification of PRC2 from nuclear 
pellet fractions suggested that PRC2 has 5 components: Ezh2, Eed, Suz12, RbAp48 
and AEBP2 (Cao et al., 2002a). The methyltransferase activity exclusively resides in 
Ezh1 and Ezh2, while Suz12 and Eed are essential for modulating the activity of the 
complex, AEBP2 is important for optimal histone methyltransferase activity towards 
H3K27me3 (Pasini et al., 2004) and the histone chaperone RbAp48 may promote 
histone binding of PRC2. More recently, Jarid2 was identified as an additional 
component of PRC2, which plays a role in recruitment of PRC2 to some target loci (Li 
et al., 2010). 
Important insights into the function of PRC2 originated from developmental 
studies in Drosophila melanogaster. The Polycomb group (PcG) proteins were 
initially identified to play key roles in the regulation of Drosophila Hox genes (Lewis, 
1978). During early Drosophila embryogenesis, PcGs function in maintaining the 
repression of Hox genes via chromatin remodeling, which can be mediated by the are 
three known PcG complexes in Drosophila: PRC1, PRC2 and PhoRC 
(Schuettengruber et al., 2007). PcGs are highly conserved in terms of function and the 
mammalian versions of these complexes have been purified biochemically and 
characterized by several laboratories. The main function of PRC2 is to repress gene 
13 	  
expression by the deposition of H3K27me3 mark (Figure 1.4). It has been shown that 
PRC2 is recruited to important developmental genes and the mode by which PRC2 
functions in maintaining the repressive state of targets is by first establishing the initial 
H3K27me3 mark and propagation of the mark. Work from Reinberg and colleagues 
has shown that the Eed subunit of PRC2 uses an aromatic cage to recognize and bind 
the H3K27me3 mark, and thereby promotes the propagation of the histone 
modification by PRC2 to adjacent histones (Margueron et al., 2009). The PRC2-
mediated H3K27me3 deposition also plays a role in the recruitment of PRC1. Briefly 
discussing the action of PRC1 in the chromatin remodeling, PRC1 binds to 
H3K27me3 via a chromo-domain of Cbx, one of PRC1 components. PRC1 generally 
consist of Bmi, RING1b, HPH and Cbx although PRC1 compositions are much more 
diverse between different complexes (Figure 1.4). RING1b is an ubiquitin E3 ligase 
that catalyzes H2AK119 ubiquitination (Wang et al., 2004). The H2AK119ub is 
thought to inhibit Pol II mediated transcriptional elongation; therefore, the target genes 
are not expressed. In addition to its role in H2AK119-dependent gene silencing, PRC1 
also represses transcription by chromatin compaction (Eskeland et al., 2010). 
Collectively, PRC1 acts as an effector protein complex for PRC2-mediated gene 
silencing mechanisms (Figure 1.4). Although PRC1 was described as an effector of 
PRC2-mediated gene repression, PRC1 also can be recruited to target genomic loci in 
a PRC2-independent fashion (Tavares et al., 2012). Therefore, recent studies have 
shown that the precise mechanisms of PRC1-dependent transcription repression are 
more complex than they were thought to be; the details will not be discussed in this 
study. 
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Figure 1.4. Polycomb Repressive Complex 2 and its function PRC2 methylates 
ARKS motif at H3K27. PRC2-mediated trimethylation of H3K27 results in 
recruitment of PRC1, which compacts chromatin and inhibits transcriptional 
elongation.  	  
1.5 The role of PRC2-mediated gene silencing in T cell immunity 
Chromatin modifications have an appreciable impact on the outcome of 
signaling pathways. Therefore, modulating chromatin structure determines the signal-
induced transcriptional fate. In T cells, epigenetic mechanisms have been implicated in 
T helper lineage differentiation. Initial studies of PRC2 in T cell immunity focused on 
the role of PRC2 in Th1/Th2 differentiation. Although the first genetic study on PRC2 
in T cells was from our laboratory (Su et al., 2005), it was unrelated to T cell effector 
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functions. By chromatin-IP (ChIP) analysis, in vitro Th2 differentiated cells were 
shown to lose H3K27me3 and Ezh2 binding at the IL-4/IL-13 locus, which can be 
found in naïve T cells (Koyanagi et al., 2005). Genetic studies have also shown that 
Ezh2 ablation leads to a gain of plasticity in Th1/Th2 differentiation (Tumes et al., 
2013; Zhang et al., 2014). In addition to the Th1/Th2 paradigm, PRC2 has been 
implicated in the epigenetic regulation of regulatory T cell differentiation and function 
(Arvey et al., 2014; DuPage et al., 2015; Yang et al., 2015). Recently, our laboratory 
reported that Ezh2 controls invariant Nature Killer T (iNKT) cell development by 
controlling PLZF expression, the master transcription factor of iNKT cell development 
and function (Dobenecker et al., 2015). 
In addition to studies on PRC2 function in T cell differentiation, the loss of 
Ezh2 in T cells results in reduced enrichment of H3K27me3 at the IFN-γ and Eomes 
loci in Th0 or iTreg cells in vitro (Zhang et al., 2014). Ezh2 was also shown to control 
survival-related gene expression such as Bcl2 in activated T cells (Zhang et al., 2014; 
Zhao et al., 2016). Along with these observations, Ezh2-deficient T cells have a defect 
in expansion in vivo or proliferation in a long-term culture in vitro.  
The physiological role of PRC2 for T cell differentiation was demonstrated by 
several studies in animal models. Loss of Ezh2 in T cells exacerbated allergen-induced 
asthma by enhancing Th2 responses (Tumes et al., 2013). On the other hand, Th1 
responses in vivo were also negatively affected by Ezh2 deficiency in pathogen 
infections such as Toxoplasma gondii and Listeria monocytogenes infections (Yang et 
al., 2015; Zhang et al., 2014). Furthermore, anti-tumor immunity required Ezh2 
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activity (Zhao et al., 2016). In summary, Ezh2 containing PRC2 governs T cell 
immunity; however, a clear mechanistic understanding is lacking.   
 
1.6 Involvement of Ezh2 in TCR-signaling induced actin polymerization 
Previous studies on PRC2 control of T cell immunity have attempted to 
explain PRC2-dependent T cell immunity by the transcriptional regulation through 
Ezh2. However, the early finding of Ezh2 as an interaction partner of the cytosolic 
protein Vav1 hints towards an additional mechanism of Ezh2 in the control of T cell 
activation, independent from its nuclear functions (Hobert et al., 1996). Vav proteins 
are important regulators for signal transduction, harboring GDP exchange factor 
(GEF) activities. Three isoforms, Vav1, Vav2 and Vav3, are expressed in mammalian 
cells (Bustelo, 2000). Among those, Vav1 expression is restricted to hematopoietic 
cells whereas Vav2 and Vav3 are expressed in a broad range of cell types. In T cells, 
Vav1 is a pleiotropic regulator for TCR signaling and absence of Vav1 impacts TCR-
induced actin polymerization as well as calcium mobilization (Costello et al., 1999). 
Vav1 acts downstream of the TCR and its activity can be regulated by TCR-induced 
tyrosine phosphorylation. In detail, Vav1 has regulatory tyrosine residues on its acidic 
domain, which stabilize an auto-inhibitory conformation found in the steady state 
(Aghazadeh et al., 2000). Upon TCR-induced phosphorylation of those tyrosine 
resides, Vav1 changes its conformation into an active form, which exposes its GEF 
domain. Ezh2 was shown to bind to the N-terminal portion of Vav1 where the auto-
inhibition takes place. Whether Ezh2 binding to Vav1 changes upon TCR stimulation 
and whether Ezh2 influences Vav1 conformation, are open questions. 
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Some known functions of Vav proteins in TCR-induced actin polymerization 
include a role as a GEF for RhoGTPases like Cdc42, Rac1 and RhoA (Bustelo, 2001; 
Turner and Billadeau, 2002). This effect is counteracted by GTPase activating proteins 
(GAPs), which induce the hydrolysis of GTP to GDP. GTP-loaded Cdc42 binds to 
WASP recruited to TCR signaling cluster by Nck. Cdc42 binding to WASP changes 
its conformation from a closed to an open conformation. This form of WASP exposes 
its C-terminal VCA domain and allows Arp2/3 to bind, thereby initiating the 
nucleation of actin for branched actin networks (Takenawa and Suetsugu, 2007). 
Alternatively, a Rac1-dependent pathway activates the WAVE2 complex in T cells to 
promote actin nucleation through Arps2/3 in a manner similar to WASP. Lastly, the 
RhoA pathway differs from Cdc42 and Rac1 in that it utilizes Dia for polymerization 
of linear actin filaments, rather than branched actin networks. Therefore, Vav1 acts 
upstream of Cdc42, Rac1 and RhoA in TCR-induced actin polymerization. 
Along with the evidence of an interaction between Vav1 and Ezh2, our 
laboratory previously reported that Ezh2 plays an indispensable role for TCR-induced 
actin polymerization (Su et al., 2005). We have shown that Ezh2-deficient T cells do 
not accumulate F-actin content upon TCR crosslinking. This effect seems to be due to 
the impairment of the cytosolic function of Ezh2, as shown by rescue experiments in 
Ezh2-deficient MEFs with Ezh2 protein that lacks the nuclear localization signal 
(Ezh2ΔNLS). Rescue was not achieved with a SET domain mutant, indicating that the 
methyltransferase activity of Ezh2 is essential for actin polymerization. Moreover, 
deletion of Ezh2 in bone marrow results in failure of normal beta-selection due to a 
signaling defect during T cell development. These data provide us with crucial 
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evidence for the signaling requirement of Ezh2 in T cells. A more recent study 
supporting the cytosolic function of Ezh2 was conducted using other cell types. 
Genetic ablation of Ezh2 in dendritic cells results in a defect in integrin-dependent 
migration (Gunawan et al., 2015). The Ezh2-deficient dendritic cells did not display 
reduced H3K27me3 level. The prevalent hypothesis in the field is that PRC2 primarily 
functions through H3K27me3. Therefore, a precise mechanistic explanation is needed 
to clarify the role of PRC2 in signaling. Furthermore, to be able to judge the 
significance of the cytosolic function of PRC2 it is important to understand the 
composition of the complex and its cytosolic substrates.  
 
1.7 Non-histone substrates of Ezh2 
When discussing the cytosolic function of Ezh2, an outstanding question is 
whether Ezh2 can methylate non-histone proteins. Indeed, there are six proteins that 
have been identified as non-histone substrates of Ezh2: Rorα, STAT3, GATA4, Fra-2, 
Jarid2 and Talin-1. Rorα K38 mono-methylation by Ezh2 interacts with DCAF1, 
which leads to destabilization of Rorα by DCAF1-DDB-CUL4 E3 ligase-mediated 
ubiquitination (Lee et al., 2012). In this study, the chromo-like domain of DCAF1 was 
shown to recognize the methyl-lysine motif generated by Ezh2, suggesting that Ezh2-
mediated lysine methylation of non-histone substrates can also function through 
“readers” as those found for histones. In addition, Ezh2 has been shown to methylate 
three transcription factors. First, STAT3 K49/K180 methylation by Ezh2 was reported 
(Dasgupta et al., 2015; Kim et al., 2013) to be required for an optimal level of STAT3 
phosphorylation, which is crucial for its transcriptional activity. Second, GATA4 is 
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methylated by Ezh2 at K299 (He et al., 2012) and this methylation leads to repression 
of the transcriptional activity of GATA4 by antagonizing its acetylation. Lastly, Fra-2 
K104me represses Fra-2 transcriptional activity in non-differentiated keratinocytes 
until differentiation is induced (Wurm et al., 2015). These examples showed that 
Ezh2-mediated lysine methylation impacted transcriptional activity and in the case of 
GATA-4 and STAT-3 Ezh2-mediated methylation affected the deposition of other 
post-translational modifications such as acetylation and phosphorylation. It was 
recently found that Ezh2 can tri-methylate Jarid2, a subunit of the PRC2 complex 
found in embryonic stem cells (ESCs), and this methylation creates a binding site for 
Eed (Sanulli et al., 2015) resulting in enhanced stimulation of PRC2 histone 
methyltransferase activity. While auto-phosphorylation is thought to be an excellent 
way of regulating enzyme activity, self-methylation may be also a conserved 
mechanism that provides an additional layer of fine-tuning of methyltransferase 
activity. Whereas all the substrates so far were implicated in regulating transcriptional 
events, Talin-1 was identified as a “true” cytosolic substrate of Ezh2 (Gunawan et al., 
2015). As mentioned above, Ezh2 regulates cell migration in leukocytes through 
histone non-related functions. Talin-1 was proposed to be methylated by Ezh2 and its 
methylation controls adhesion turnover by dissociating Talin-1 from actin. 
Interestingly, actin and the actin binding protein EF1α1 were found to be methylated 
(Li et al., 2013; Vermillion et al., 2014), suggesting that lysine methylation has a 
significant contribution to actin cytoskeleton remodeling. Despite the identification of 
Talin-1 methylation, the previously observed function of Ezh2 in TCR-induced actin 
polymerization is yet to be clarified. One caveat of the reports described above is that 
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there is no information on the stoichiometric levels of methylation in vivo. Lysine 
methylation was shown by in vitro biochemical assays or mass spectrometric analysis 
of in vitro reactions. Even though these modifications were further validated by 
antibody-based approaches in vivo, it will be interesting to determine the levels of 
lysine methylation of non-histone substrates of Ezh2, although it may be technically 
difficult due to low levels found in vivo.   
Non-histone substrates of PRC2 can be classified into two categories by 
comparing the similarity of their target sequences to the target sequence in histone H3. 
The first group of substrates contains a histone-like sequence. The “reader” proteins of 
modified histones do not recognize the whole protein but rather a short amino acid 
sequence (Li et al., 2007). This indicates that a short motif is sufficient to provide a 
methylation platform and its methylation can be recognized by conserved methyl-
binding domains (Fischle et al., 2003). Our laboratory made the exciting discovery 
that such motifs can also be found in non-histone proteins. Self-methylation of G9a 
was identified at the histone-like sequence (K9-like sequence, ARKT) residing in the 
G9a protein (Sampath et al., 2007). This self-methylated lysine residue is recognized 
by the chromo-domain containing protein HP-1. Interestingly, Rorα methylation was 
identified by a bioinformatics screening for the histone-like sequence (RKS). The 
second class of substrates does not contain consensus sequences around methylation 
sites. Therefore, it is likely that Ezh2 methylates its target in a semi sequence-specific 
manner.  
?
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Table 1.1. List of identified substrates of Ezh2 
Substrates 
Lysine 
residue 
Target 
sequence 
Methylation 
state 
Biochemical 
outcome 
Biological 
function 
 
H3 K27 ARKSA Di-, Tri- 
Protein-
protein 
interaction 
Transcriptional 
repression 
Histone-
like 
sequence RORα K38 ARKSE Mono- 
Decreasing 
protein 
stability 
Transcriptional 
activity 
STAT3 
K49 ASKES  Di- Unknown 
Transcriptional 
activity K180 YMKLH Mono- 
Promoting 
Other 
modification 
No 
sequence 
consensus 
GATA4 K299 TLKSQ Mono- 
Inhibiting 
Other 
modification 
Transcriptional 
activity 
FRA2 K104 VIKTI Mono-, Di- Unknown 
Transcriptional 
activity 
JARID2 K116 QRKFA 
Mono-, Di- 
(In vitro) 
Di-, Tri-  
(In vivo) 
Protein-
protein 
interaction 
Transcriptional 
repression 
Talin-1 K2454 AMKRL Tri- 
Protein 
cleavage 
Adhesion 
turnover 
 	  
1.8 Biochemical functions of lysine methylation 
Methyl-groups are relatively small and do not grossly change the chemical 
properties of proteins. While acetylation neutralizes the positive charge on lysine 
residues for example, methylation does not change the charge of the amino acid but 
plays a critical role in many biological processes (Figure 1.5).  
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First, lysine methylation can modulate post-translational modification of 
neighboring amino acids. A phosphorylation-methylation switch that was discussed 
above represents such a function. However, lysine methylation does not always inhibit 
the phosphorylation of neighboring residues. It can also promote the phosphorylation 
as shown in Rb methylation by Smyd2 as residue S811 of Rb is more phosphorylated 
upon K810 methylation (Cho et al., 2012). Also, methyl-lysine serves as a recruitment 
platform of other modifying enzymes and therefore facilitates additional modifications 
on other residues. One example is the recruitment of the acetyltransferase Tip-60 to 
p53, methylation of p53 by SET7/9 (Kurash et al., 2008), allows it to interact with 
Tip-60. 
Another function of lysine methylation is to modulate protein stability. Since 
ubiquitination is also a posttranslational modification of lysines, prior lysine 
methylation can prevent proteins from being ubiquitinated. At the same time, as 
shown for Rorα methylation, lysine methylation can promote protein degradation 
through the recruitment of an E3 ligase (Lee et al., 2012). Therefore, lysine 
methylation can both increase and decrease protein stability. 
As methyl-lysine binding proteins are being discovered, the main function of 
lysine methylation seems to serve as binding modules for those proteins. PHD finger, 
Tudor, MBT, chromo-domain, PWWP and WD-repeat are representative domains for 
methyl-lysine binding (Maurer-Stroh et al., 2003; Yap and Zhou, 2010). However, 
lysine methylation can not only promote but also hamper protein-protein interactions. 
Smyd3-mediated MAP3K2 methylation inhibits interaction between MAP3K2 and the 
phosphatase PP2A. Both promotion and inhibition of interactions by lysine 
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methylation strongly indicates that despite the small addition of “bulk” by the methyl-
group to lysines, structural elements allow to clearly distinguish between methylated 
and non-methylated proteins. 
 
   
	  
 
Figure 1.5. Biochemical functions of lysine methylation 1) Lysine methylation can 
provide docking sites for several proteins. Histone modification is a good example to 
demonstrate how lysine methylation can assemble an array of different “readers” 2) 
Since lysines can be target sites of E3 ligases, methylation can prevent ubiquitination-
mediated protein degradation. 3) Lysine methylation can modulate protein 
interactions. This function includes both promotion and inhibition of interactions.  	  
1.9 Aims of this study 
In this study, we sought to understand the cytosolic functions of PRC2 in TCR-
mediated T cell activation. We show that H3K27me3 levels are not altered in 
peripheral T cells of Ezh2fl/fl; CD4-cre mice. Therefore, peripheral T cells from these 
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mice with wild-type surface-marker expression and wild-type gene expression pattern 
can be used as an excellent model for studying the nuclear and non-nuclear function of 
PRC2 in T cell activation and we will discuss the role of PRC2 in TCR-driven T cell 
expansion in vivo and in vitro. 
Using the peripheral T cells with the genetic deletion of PRC2, we have found 
that TCR-mediated Erk phosphorylation was impaired in the absence of PRC2. Along 
with the previously described defect in TCR-induced actin polymerization pathway, 
we propose that PRC2 deficient T cells may have direct signaling defect in a fashion 
independent of histone modification. Signaling defects in PRC2-deficient mice could 
be indirect effects from some dysregulated gene that accumulated developmentally. 
Therefore, we will provide direct evidence of the cytosolic function of PRC2 for TCR 
signaling by three independent approaches. First, we examined the complex 
composition and properties in the cytosol. Understanding the components of cytosolic 
PRC2 (cPRC2) might also help us to understand why cPRC2 is essential for TCR 
signaling. Second, we will utilize pharmacological inhibition of PRC2. This approach 
will allow us to query the function of cPRC2, without having to worry about altered 
gene-expression, since we can utilize wild-type cells and short-term incubation with 
the inhibitor on ice, minimizing any nuclear changes. Also, it will allow us to 
distinguish between a possible adaptor function and the requirement of the 
methyltransferase activity of cPRC2 for TCR signaling. Finally, we identified Nck1 as 
cytosolic substrate of cPRC2. This allows us to determine where cPRC2 functions in 
the signaling cascade downstream of the TCR.  
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Lastly, we study the cPRC2-mediated lysine methylation dependent interaction 
partners of Nck1. This research has the potential to discover a formerly unappreciated 
mechanism that controls receptor-mediated signaling events.  
 
1.10 Hypothesis  
The fact that one of the key chromatin regulators, PRC2, directly controls TCR 
signaling is a very intriguing aspect of biology. This apparent moonlighting of a 
nuclear complex in the cytoplasm may act as a safeguard mechanism for cells to keep 
themselves from abnormal gene expression. H3K27me3 marks are very stable even in 
the absence of PRC2. H3K27me3 can be actively removed (Agger et al., 2007) or 
passively diluted in the absence of PRC2 by cell division and the necessity for new 
nucleosomes. Lack of H3K27me3 leads to altered gene-expression (Cao et al., 2002a). 
Therefore, maintaining sufficient amounts of PRC2 in dividing cells is crucial and 
indeed PRC2 expression drastically increases upon mitotic stimulation. Making PRC2 
an integral and necessary component of the signaling cascade that can induce 
proliferation would ensure that only those cells divide that have sufficient enzyme 
complex in the cells. In addition, ensuring its enzymatic activity is important for 
proper gene regulation, therefore, such a safeguard mechanism should utilize common 
enzymatic properties in both signaling and epigenetic regulation to a certain degree. 
Therefore, we hypothesize that PRC2 directly controls TCR-mediated T cell activation 
by methylating a cytosolic substrate. This study reveals a novel signaling paradigm 
involving lysine methylation.    
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Mice 
Previously generated Ezh2fl/fl ; CD4-Cre mice (Su et al., 2003; Su et al., 2005) 
were crossed with Ezh1-/- mice, which were generated by Dr. Donal O’Carroll 
(Thomas Jenuwein Lab), to give rise to Ezh1-/- Ezh2fl/fl;CD4-Cre mice on B6/129 
background. For testing single knockout for Ezh2, Ezh2fl/fl ; CD4-Cre mice on 
C57BL/6 background were used. Eedfl/fl mice on C57BL/6 background were kindly 
gifted from Dr. Meinrad Busslinger and crossed with CD4-Cre mice. To obtain a large 
number of cells, C57BL/6 mice were used for harvesting lymph nodes and spleens. 
 
2.2 Infection 
2 x 105 PFU per mouse of LCMV Armstrong was infected by intra-peritoneal 
injection. Peripheral Blood Mononuclear cells (PBMC) and serum were obtained from 
infected mice by retro-orbital bleeding on post-infection day 5, 8, 15 and 123. To 
analyze the virus-specific T cell responses, spleen and lymph nodes. Lung tissue was 
harvested to measure viral titer. Normal kinetics of virus-specific T cell responses is 
shown below. To examine the effector phase of immune response, the infected mice 
were sacrificed on post-infection day 8 and splenocytes were analyzed. 
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Figure 2.1.	   Kinetics of virus-specific T cell response Number of clonal T cells 
specific to virus is small at naïve T cell stage. Once virus evades, T cells that 
recognized the antigen expanded. Detection of virus-specific T cells can be done from 
5 days after infection. Peak of CD8 T cell response is on day 8, followed by 
contraction phase where massive cell death of effector cells occurs. A significant 
number of virus-specific T cells remain even after the contraction phase, and they 
form memory T cell population. 	  
2.3 Virus productions and plaque assays 
LCMV Armstrong was produced in Baby Hamster Kidney (BHK) 21 cell 
lines. Monolayer of BHK21 cell line was infected with LCMV Armstrong at MOI of 
0.3. Infection was done for 1 hr on rockers at 37°C. Pre-warmed DMEM media 
containing 10% FBS and 1% Penicillin/streptomycin were given to the infected cells. 
After 48 hrs, the media was harvested and spin down to get supernatant. The virus was 
titrated prior to use for in vivo experiments. 
Virus titration was done by plaque assay. Serum was obtained by 
centrifugation of blood for 10min at 13000rpm. To isolate virus from tissues, tissues 
were homogenized in 1ml of media and spun down. Vero cells were grown for the 
plaque assay. Vero cells were infected with serum or harvested virus, which were 
diluted into proper range, for 1hr with shaking at 37°C. After infection, the infected 
0 16 8 30 
CD8 T 
cell 
response 
5 
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cells were incubated with 199 Media containing 10% FBS, 1% 
Penicillin/streptomycin, 1% L-glutamate and 0.5% agarose. After 4 days, the cells 
were stained overnight with 199 Media containing 0.5% neutral red with other 
supplements listed above. Plaques, which are seen as regions without cells, were 
counted and PFU was calculated according to dilution and the number of plaques.  	  
2.4 Flow cytometry and detection of virus-specific T cells 
Virus-specific T cells were detected using peptide-MHC class I tetramers. 
Monomers for LCMV GP33-41, GP276-286 and NP396-404 were obtained from NIH 
tetramer core facility. Monomers were tetramerized with PE-conjugated streptavidin 
on ice for 1hr. Using flow cytometric analysis, frequency of virus-specific CD8 T cells 
and activation of T cells were examined. BD LSR II was used for flow cytometry and 
acquired data were analyzed with Flow Jo.  
 
2.5 Restimulation of T cells for cytokine production 
To measure virus-specific T cell response, cytokine production from T cells 
was examined. Splenocytes were stimulated with 0.2 µg/ml of GP33-41, GP276-286, 
NP396-404 and GP61-80 for 5 hrs at 37°C in the presence of Golgi stop and Golgi plug 
(BD Biosciences). The stimulated cells were harvested and permeabilized with Foxp3 
staining kit (eBioscience). Cells were stained for IFN-γ, TNF-α and IL-2, followed by 
acquisition by flow cytometry. 
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2.6 CFSE labeling and Stimulation of T cells 
CD4 T cells were isolated from spleen and lymph nodes by MACS 
purification. Purified CD4 T cells were washed with PBS two times and labeled with 
CFSE at the final concentration of 2.5µM for 10min at room temperature. Labeling 
was stopped by FBS and washed with PBS three times. Labeled cells were stimulated 
on 96-well plates coated with 10 µg/ml of anti-CD3 and 2.5 µg/ml anti-CD28 
antibodies or with 5 ng/ml of PMA plus 0.3 µg/ml of Ionomycin in a humidified 37°C, 
5% CO2 incubator. Cells were harvested after overnight and 3 days after stimulation.  
 
2.7 Cell fractionation and Western blot 
Purified CD4 T cells were lysed with 0.5% NP-40 containing TMSD lysis 
buffer (40mM Tris-HCl pH7.9, 5mM MgCl2, 250mM Sucrose, 1mM dithiothreitol 
(DTT), 0.5% NP-40 (IGEPAL), protease cocktails (Sigma Aldrich), phosphatase 
cocktails (Millipore)) on ice for 15 min. The subcellular compartments were 
fractionated by centrifugation at 800xg for 10 min. Supernatant was further spun down 
to remove residual pellets, which supernatant was used as a cytosolic fraction. The 
pellets from centrifugation were washed twice with lysis buffer, then, incubated with 
high salt lysis buffer (50mM Tris-Hcl pH7.9, 420mM NaCl, 20mM NaF, 1mM 
EDTA, 1mM EGTA, 1.5mM MgCl2, 10% glycerol, protease cocktails (Sigma 
Aldrich), phosphatase cocktails (Millipore)) for 10 min on ice. The extracts were 
sonicated for 10 cycles (30s per cycle), followed by centrifugation at 13000 rpm for 15 
min, to obtain a nuclear extract. The concentrations of extracts were measured by 
standard BCA assay. The fractionated extracts or whole cell lysates were separated by 
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SDS-PAGE and transferred to a polyvinylidene difluoride membrane. The membrane 
was incubated with primary antibodies, followed by horseradish peroxidases 
conjugated secondary antibodies and developed with ECL systems according to 
manufacturer’s instructions.  
 
2.8 Erk phosphorylation assay 
Purified CD4 T cells were incubated with 10 µg/ml of anti-CD3 antibody 2.5 
µg/ml of anti-CD28 antibody on ice for 20 min, followed by cross-linking with 20 
µg/ml of anti-Armenian Hamster IgG secondary antibody for 2 min or 10 min at 37°C. 
For PMA stimulation, cells were incubated with pre-warmed media containing 5ng/ml 
of PMA for 10min at 37°C. Cells were washed with cold BSS media, then, lysed with 
0.5% of NP-40 lysis buffer (50mM Tris-Hcl pH7.9, 150mM NaCl, 20mM NaF, 1mM 
EDTA, 1mM EGTA, 1.5mM MgCl2, 10% glycerol, 0.5% NP-40, protease cocktails 
(Sigma Aldrich), phosphatase cocktails (Millipore)) for 15min on ice. Lysates were 
obtained by centrifugation. The phosphorylated Erk1/2 were detected by western blot 
analysis using rabbit anti-phospho-Erk1/2 (T202/Y204) antibody (D13.14.4E, Cell 
Signaling Technologies) and mouse anti-Erk antibody (L34F12, Cell Signaling 
Technologies). 
 
2.9 Immunoprecipitation 
The fractionated lysates or lysates obtained by using ODG lysis buffer (2% of 
N-Octyl-β-D-Glucopyranoside, 50mM Tris-Hcl pH7.9, 150mM NaCl, 20mM NaF, 
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1mM EDTA, 1mM EGTA, 1.5mM MgCl2, 10% glycerol, protease cocktails (Sigma 
Aldrich), phosphatase cocktails (Millipore)) were incubated with antibodies cross-
linked to protein G dynabeads. The cross-linking of antibodies to beads was achieved 
by using BS3 cross-linker. Immunoprecipitates were washed with lysis buffer and 
eluted by boiling in sample loading buffer. Co-immunoprecipitates were detected by 
western blot analysis.   
 
2.10 Streptavidin immunoprecipitaion for TCR 
Purified CD4 T cells were incubated with anti-CD3/anti-CD28 antibodies, 
followed by biotinylated anti-Armenian Hamster IgG secondary antibodies for 2min at 
37°C. For unstimulated cells, secondary antibodies reaction was done on ice for 15 
min. Cell were lysed in ODG lysis buffer, followed by centrifugation. The supernatant 
were obtained and incubated with M-280 streptavidin beads for 2 hrs. Co-
immunoprecipitates were analyzed by western blot analysis.  	  
2.11 In vitro methyltransferase assay 
In vitro methyltransferase assay was performed in methyltransferase assay 
buffer (50 mM Tris-HCl pH 8.5, 5 mM MgCl2 and 1 mM DTT) with 0.69 µM of 3H-
SAM (Perkin Elmer) or 80 µM of SAM (NEB). 100 µM of peptides or 1 µg of 
proteins were used as substrates. 0.67 pmol of recombinant PRC2 containing Ezh2, 
Eed, Suz12, RbAp48 and AEBP2 (BPS Biosciences) was used for the 
methyltransferase reaction. The reaction was performed for 1hr 30min at 37°C and 
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stopped by adding sample loading buffer, followed by boiling. The reactants were 
loaded on SDS-PAGE gel, followed by incubating with Enhance solution (Perkin 
Elmer), and the methylation was probed by autoradiography.  
 
2.12 Differential salt wash 
Co-immunoprecipitates were incubated with Tris-HCl pH 7.9, 0.2mM EDTA, 
5% Glycerol, 5mM DTT, differential concentration of NaCl (150mM to 600mM) for 
30 min three times. Co-immunoprecipitates were further washed twice with 150mM 
NaCl buffer and eluted by boiling in sample loading buffer.  
 
2.13 Human CD4 T cell and Jurkat cell stimulation 
Human blood purchased from New York Blood Center for isolating CD4 T 
cells from PBMC. CD4 T cells were purified from human blood using RossetteSepTM 
(Stem Cell Technologies). Purified T cells were pre-incubated with 10 µg/ml of mouse 
anti-human CD3 antibody (OKT3, eBioscience) for 15min on ice, followed by 
treatment of 20 µg/ml of F(ab’)2 Goat anti-mouse IgG (H+L) secondary antibody 
(Thermo Scientific) for 2 min at 37°C. The stimulated cells were immediately washed 
with ice cold PBS and lysed with NP-40 lysis buffer. Phospho-Erk1/2 was measured 
by western blot analysis on human CD4 T cell lysates. 
For Jurkat T cells, pre-warmed media containing 10 µg/ml of OKT3 was 
treated to the cells for 2 min at 37°C. Then, Jurkat cells were washed in cold PBS and 
lysed as described above. We also used J.Vav (Vav1-deficient Jurkat cell line) and 
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Nck1/2 knockdown Jurkat cells (ShRNA-mediated knockdown) (Cao et al., 2002b; 
Ngoenkam et al., 2014) for this experiment.  
 
2.14 Antibodies 
For Co-immunoprecipitation experiments, rabbit anti-Ezh2 antibody (D2C9, 
Cell Signaling Technologies), rabbit anti-Nck1/2 antibody (C-19, Santa Cruz Biotech), 
rabbit anti-Vav1 antibody (C-14, Santa Cruz Biotech) were used. For western blot 
analysis, mouse anti-Ezh2 antibody (Clone 11, BD biosciences), goat anti-Suz12 
antibody (P-15, Santa Cruz Biotech), mouse anti-Vav1 antibody (05-219, Millipore), 
mouse anti-Nck antibody (Clone 108, BD biosciences), mouse anti-RbAp48 antibody 
(11G10, Abcam), rabbit anti-Jarid2 antibody (ab48137, Abcam). Anti-Eed rabbit and 
anti-Ezh1 antibodies were kindly provided by Danny Reinberg at NYU. For 
investigating TCR interaction with Ezh2, rat anti-CD3 antibody (CD3-12, Cell 
Signaling Technologies) was used. For measuring global levels of H3K27me3, rabbit 
anti-H3K27me3 antibody (07-449, Millipore) was used. For examining TCR-induced 
phosphorylation, mouse anti-PLCγ1 antibody (05-163, Millipore), rabbit anti-
phospho-PLCγ1 (Y783) antibody (#2821, Cell Signaling Technologies), mouse anti-
phospho-tyrosine antibody (4G10, Millipore), rabbit anti-phospho-Akt (T308) 
antibody (C31E5E, Cell Signaling Technologies), rabbit anti-phoshpo JNK 
(T183/Y185) antibody (#9251, Cell Signaling Technologies), goat anti-JNK antibody 
(C-17, Santa Cruz Biotech) and rabbit anti-phospho-Vav (Y174) antibody (sc-16408, 
Santa Cruz Biotech). For detection of methyl-lysines, rabbit anti-pan-methyl lysine 
antibody (#23366, Abcam) was used.  
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2.15 ChIP-Sequencing 
Chromatin immunoprecipitation was performed as previously described (Lee 
et al., 2006). Purified CD4 T cells were cross-linked with 0.5% formaldehyde at RT 
for 10 min. Cells were lysed in RIPA lysis buffer containing 0.3M NaCl, followed by 
sonication. Sonicated extracts were incubated with antibodies bound to protein G 
overnight. Beads were washed with modified RIPA wash buffer containing 100mM 
LiCl and TE. De-crosslinking was done overnight at 65°C, followed by Rnase / 
Proteinase K treatement. ChIPed DNA and Input DNA were purified using Qiaquick 
PRC purification kit (Qiagen). ChIP was further validated by qPCR using SYBR 
Green PCR reagents and LightCycler 480. ChIPed DNA was generated into blunt-end 
DNA using DNA EndRepair kit (Epicenter Biotechnologies) according to the 
manufactuere’s instructions. PCR purified end-repaired DNA was incubated with 
Klenow fragment (M0212, New England BioLabs) to add ‘A’ bases to the DNA. After 
PCP purification using MiniElute kit, the DNA fragments were ligated with 
Illumina/Solexa adaptors using T4 DNA ligase (New England BioLabds). With 
Illumina/Solexa primers 1.0 and 2.0, the DNA fragments were PCR amplified for 18 
cycles. The ChIP-Seq library was further purified by MiniElute Kit, followed by 
sequencing on Illumina Hi-Seq 2000 for 50 cycles. The raw sequencing data were 
processed using CASAVA_v1.8.2 software to generate fastq files and aligned to the 
mouse genome (mm9) using Bowtie v0.12.7. Reads were filtered by alignment with 
more than 2 errors and more than 2 locations in the genome. For comparative analysis 
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of promoter regions, the number of aligned reads in the ±3 kb area from transcription 
start site of each gene was analyzed.  
 
2.16 RNA-Sequencing 
2µg of total RNA were used and ribosomal RNA was removed using Ribo-
Zero Magnetic kit (Epicenter). RNA-Seq library was prepared with ScripSeq v2 RNA-
Seq Library Preparation Kit (Epicenter) following the manufacturer’s instructions. In 
brief, purified RNA was fragmented, followed by cDNA synthesis, adaptor ligation 
and pre-amplification. Samples were sequenced as described above with 100 cycles of 
amplification. Fastq reads were aligned to the mouse genome (mm9) using Tophat to 
account for splicing, alternative promoter usage, insertions and deletions. Also, 
differential gene expression, alternative promoter usage and splicing variant were 
analyzed using Cufflinks RNA-seq analysis tool.  
 
2.17 Statistical analysis 
Statistical analysis was performed in Prism (Graphpad) with the unpaired two-
tailed Student’s t-test. Data were present as mean ± standard deviation in most of 
figures. 
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CHAPTER 3: CONTROL OF TCR-MEIDATED T CELL ACTIVATION BY 
PRC2  
3.1 Expression of Ezh1 and Ezh2 
Ezh1 and Ezh2 are the catalytic subunits of PRC2 responsible for the 
methyltransferase activity of the complex. These enzymes are structurally very similar 
to each other and share 76% sequence identity. Particularly the SET domains, which 
are essential for the methyltransferase activity of Ezh1 and Ezh2 share a 96% 
sequence identity between them.  
 
 
	  
Figure 3.1. Domain structures of Ezh1 and Ezh2  Ezh1 and Ezh2 have the same 
domain structure with high sequence homology. Both of their enzymatic domains 
(SET) are located at the C-terminus and share 96% sequence identity.  
 
However, the relative contribution of Ezh1 and Ezh2 for T cell immunity has 
not been addressed. Despite their structural similarity, Ezh1 and Ezh2 have quite 
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different expression patterns in T cells. Upon mitotic stimulation including TCR or 
PMA/Ionomycin, T cells up-regulat Ezh2 drastically whereas Ezh1 expression is 
relatively constant. This indicates that Ezh1 and Ezh2 may have differential 
contributions to T cell biology. 
 
	  
Figure 3.2. Selective upregulation of Ezh2 in activated T cells A. Ezh2 is up-
regulated in CD4 T cells stimulated with anti-CD3 and anti-CD28 antibodies for 5 
min, 30 min and 12hrs, compared to naïve T cells. Ezh1 expression is not up-regulated 
in activated T cells B. PMA and Ionomycin stimulation induces a significant increase 
in Ezh2 expression while Ezh1 expression is relatively stable. 
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3.2 Normal T cell development in the absence of PRC2 in T cells 
To examine the role of PRC2 in TCR-mediated T cell activation, we developed 
animal models combining the Ezh2 conditional knockout (Ezh2fl/fl) with CD4-cre in an 
Ezh1 null background (Ezh1-/-). Additionally, we also targeted another component of 
the PRC2 complex, Eed by crossing Eedfl/fl mice with CD4-Cre mice to generate 
conditional knockout of Eed in T cells. In these mouse models, Ezh2 and Eed deletion 
occur in the double-positive thymocyte stage and allow the generation of Ezh2 and 
Eed deficient peripheral T cells. Since PRC2 is implicated in gene regulation during 
development, we examined whether our mouse models had developmental defects. 
We did not observe any gross defect in T cell development in these mice. Ezh1-/-
Ezh2fl/fl;CD4-Cre mice (PRC2 knockout mice), and Eedfl/fl;CD4-Cre mice (Eed 
conditional knockout) were normal in terms of CD4 and CD8 ratio in peripheral 
lymphoid tissues and thymus (Figure 3.3 and Figure 3.4). Our laboratory reported that 
Ezh2fl/fl;CD4-Cre mice (Ezh2 conditional knockout mice) have a bystander effect in 
activation of CD8 T cells due to the increased number of iNKT cells (Dobenecker et 
al., 2015). However, this phenotype disappeared when Ezh2 was ablated along in the 
Ezh1 null background (Figure 3.3A,B). In other words, there was no bystander effect 
in CD8 T cell activation and expansion was observed in lymphoid organs (Figure 
3.3A,D). As reported for Ezh2 conditional knockout mice (Dobenecker et al., 2015; Su 
et al., 2005), PRC2 knockout mice also do not exhibit any obvious alterations in their 
CD4+ T cell populations (Figure 3.3C). In accordance, CD8 and CD4 frequencies in 
thymus, spleen and lymph nodes of Eed conditional knockout mice were comparable 
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to wild-type controls (Figure 3.4A). Since Eed is essential for the assembly of the 
complex and subsequently, the enzymatic activities of both Ezh1 and Ezh2, we 
predicted that T cell phenotypes of Eed conditional knockout mice would phenocopy 
PRC2 conditional knockout mice and not Ezh2 conditional knockout mice. We found 
that Eed conditional knockout mice lack iNKT cells like the PRC2 conditional 
knockout mice (Figure 3.3B, 3.4B) and therefore did not display any bystander effect 
activation of the CD8+ T cell population (Figure 3.4D). Activation markers of CD4+ 
and CD8+ T cells displayed similar patterns in terms of CD44 and CD122 expression, 
compared to wild-type control (Figure 3.4C,D). Also, the expression of CD62L, a 
lymphoid homing marker, was not changed upon Eed deletion, indicating that T cell 
homing to secondary lymphoid organs was intact (Figure 3.4C, D left panels). We 
previously observed that Ezh1-/- mice have no T cell phenotype, including iNKT cell 
development (data not shown). 
Therefore, we conclude that PRC2 deficient mice do not have participate in 
CD4+ or CD8+ T cell development. This allowed us to use peripheral CD4+ T cells 
from Ezh1 knockout, Ezh2 conditional knockout and PRC2 knockout mice to 
investigate the role of PRC2 in T cell activation.  
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Figure 3.3. Phenotype of peripheral CD4+ and CD8+ T cells is unaffected by T cell 
specific deletion of Ezh1/2. A. The ratio of CD4+ and CD8+ T cells was examined in 
thymus, spleen and lymph nodes by flow cytometry. B. Cells were stained for CD1d 
tetramer and TCR-β to define iNKT population.   C, D. Activation phenotype of 
splenic and lymph node CD4+ T cells (C) and CD8+ T cells (D). Cells were stained for 
CD44 and CD62L. (WT: Ezh2f/f, PRC2-/-: Ezh1-/-Ezh2f/f;CD4-Cre) 
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Figure 3.4. Normal CD4/CD8 T cell development in Eed conditional knockout 
mice. A.	  Distribution of CD4+ and CD8+ T cells in thymus (upper), spleen (middle) 
and lymph nodes (bottom) was analyzed by flow cytometry. B. Cells from thymus, 
spleen and lymph nodes were stained for CD1d tetramer and TCR-β to define iNKT 
population. C. Expression of activation marker CD44 and homing marker CD62L in 
CD4+ T cells (left). CD44 and IL15-receptor CD122 (right). D. Expression of 
activation markers in CD8+ T cells. (WT: Eedf/f, cKO: Eedf/f;CD4-Cre) 	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3.3 Unaltered H3K27me3 and gene expression in naïve PRC2-deficient T cells 
Since the nuclear function of PRC2 in histone modification is well known we 
addressed the epigenetic state and gene expression pattern in PRC2 deficient 
peripheral T cells. We approached the problem in three different ways. First, we 
performed western blot analysis on lysates from naïve CD4 T cells purified from wild-
type, Ezh1-/-, Ezh2fl/fl;CD4-Cre and Ezh1-/- Ezh2f/f;CD4-Cre mice (PRC2-/-). We also 
purified the cells from Eedfl/fl mice and Eedf/lfl;CD4-Cre mice. Global levels of 
H3K27me3 in naïve CD4 T cells were not affected by deletion of Ezh1, Ezh2 and Eed 
in T cells (Figure 3.5A,B). Next, we also examined the levels of H3K27me3 in PRC2 
deficient T cells at a single cell level using flow cytometry. Ezh2-/- or PRC2-/- T cells 
exhibited similar levels of H3K27me3 in comparison to wild-type T cells (Figure 
3.5C). PRC2 deficient naïve CD8+ T cells also showed the same levels of H3K27me3 
to wild-type CD8+ T cells (Figure3.5C, right). In addition, to examine the impact of 
PRC2 on local levels of H3K27me3, we have performed a genome-wide analysis on 
H3K27me3 by ChIP-Seq. Compared to wild-type T cells, Ezh1-/-,  
Ezh2-/- and PRC2-/- T cells have comparable levels of H3K27me3 in a genome-wide 
scale (Figure 3.5D). Additionally, RNA-seq data show that all the mutants have very 
few changes in gene expression, compared to wild-type cells (Figure 3.5E). 
Collectively, PRC2 deficient naïve T cells show wild-type like patterns of H3K27me3 
and gene expression. These data imply that H3K27me3 is highly stable in undividing 
cells like naïve T cells.  
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Figure 3.5. PRC2 deficiency exhibits wild-type pattern of H3K27me3 and gene 
expression in naïve T cells A, B. Western blot analysis on cell lysates for H3K27me3 
and H3. C. Flow cytometric analysis of H3K27me3 levels in CD4+ (left) and CD8+ 
(right) T cells. Each genotype of mutants is indicated by different colors. Solid Grey 
area represents negative control for H3K27me3 staining (non-permeabilized cells) D. 
Genome-wide H3K27me3 association with individual genes in naïve wild-type and 
mutant T cells, determined by ChIP-Seq analysis for H3K27me3. Diagonal lines 
indicate 2-fold changes between wild-type and mutants. E. Gene expression levels 
were determined by RNA-Seq. Levels of mRNA of each gene in wild-type and mutant 
cells were plotted. Diagonal lines indicate 2-fold changes between wild-type and 
mutants. PRC2-/- represents T cells from Ezh1-/-Ezh2f/f;CD4-Cre mice. 
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3.4 Selective role of PRC2 in TCR-mediated T cell proliferation in vitro 
Our genetic models provide us with an excellent tool for understanding the role 
of PRC2 in TCR-mediated T cell activation. First, T cells from conditional knockout 
mice, as discussed above, do not have developmental defects. Second, our models do 
not to have abnormal gene expression, which could directly impact TCR signaling. 
Therefore, by utilizing these animal models we can investigate the role of PRC2 in T 
cell activation by measuring the proliferation capacity of PRC2 deficient T cells upon 
TCR stimulation. To induce proliferation by TCR stimulation, we stimulated CFSE-
labeled T cells on plate-bound with anti-CD3 antibody. Whereas wild-type T cells 
divided at least five times upon anti-CD3 stimulation, PRC2-deficient T cells failed to 
proliferate (Figure 3.6A). Ezh1 deficiency did not have any effect on TCR-induced T 
cell proliferation. Ezh2-/- T cells displayed only a minor defect in proliferation, 
however, we observed some variation between experiments. Although we reported 
before that Ezh2-/- T cells have a defect in TCR-induced proliferation (Su et al., 2005), 
Ezh2-/- T cells proliferated quite normally in our hands. This discrepancy may be due 
to the two different experimental methods used. In the previous publication 
proliferation was measured by 3H incorporation, while this set of data determined 
proliferation by CFSE dilution. If cells massively died right after stimulation, 3H 
incorporation assay will show the major defect. However, this seems to be not the case 
since we observed no difference in survival one day after stimulation (Data not 
shown). Therefore, it is likely that other factors such as genetic background or age 
might be involved in these diverging experimental outcomes. Along with deficiency in 
Ezh1 and Ezh2, Eed deletion caused a dramatic defect in TCR-induced cell 
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proliferation (Figure 3.6B). Since Eed is essential for Ezh1 and Ezh2 enzymatic 
activity, this result suggests that Ezh1 and Ezh2 in the context of a complex with Eed 
are important for TCR-mediated T cell proliferation. The data also confirm that Eed 
knockout is equivalent to Ezh1 and Ezh2 double knockout. Co-stimulation of anti-
CD28 antibody only partially rescued the phenotype (Figure 3.6A,B) and IL-2 failed 
to rescue the defect (Data not shown). On the other hand, PRC2 deficient T cells and 
Eed knockout T cells proliferated normally when they were treated with 
PMA/Ionomycin, which bypass the proximal signaling (Figure 3.6A,B). These data 
indicate, that PRC2 deficient T cells are capable of proliferating in principle but they 
cannot proliferate in response to TCR stimulation, due to a defect in signaling. In other 
words, PRC2 is required for receptor proximal signaling events, but dispensable for 
gene regulation in resting naïve T cells.  
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Figure 3.6. PRC2 deficient T cells fail to proliferate upon TCR stimulation A. 
CFSE labeled wild-type and indicated mutant CD4+ T cells were stimulated with anti-
CD3 antibody (upper), anti-CD3/anti-CD28 antibodies (middle) and PMA/Ionomycin 
(bottom) for 3 days. Cell division was assessed by CFSE dilution. B. Eed-/- T cells and 
littermate controls were stimulated as described above. Red solid graph represents 
cells cultured in media alone for 3 days. Data are representatives of at least two 
independent experiments with two or three biological replicates in each experiment. 
49 	  
3.5 PRC2 controls TCR-mediated Erk phosphorylation 
To explore how PRC2 controls TCR induced proliferation, we examined the 
TCR signaling cascade in PRC2 deficient T cells. Tyrosine phosphorylation of 
multiple substrates including Zap70, Vav and PLCγ1 initiate TCR signaling. We 
found no defect in the phosphorylation of these proteins upon TCR stimulation (Figure 
3.7A). As discussed earlier, TCR engagement activates several signaling pathways 
including the MAPK pathway and the PI3K pathway. While we did not see defective 
phosphorylation of JNK and Akt, we found a significant reduction (nearly 70% at 2 
min after stimulation) in phosphorylation of Erk1/2 in Ezh2 deficient and PRC2 
deficient T cells, compared to wild-type controls (Figure 3.7A). The MAPK pathway 
is known to control TCR induced proliferation (Alberola-Ila et al., 1995; Pages et al., 
1999), which is why the defect in Erk activation might explain the lack of 
proliferation. To test, if the defect is truly a signaling defect and not a general defect in 
the MAPK pathway, we stimulated Ezh2 and PRC2 deficient T cells with 
PMA/Ionomycin and analyzed Erk phosphorylation. Neither Ezh2 nor PRC2 deficient 
T cells showed a defect in PMA/Ionomycin induced Erk phosphorylation (Data not 
shown), confirming that the defect observed after TCR stimulation is most likely a 
signaling defect and does not reflect a general inability of these cells to activate the 
MAPK pathway. As an additional control we induced robust Erk phosphorylation in 
PMA/Inonmycin expanded, rested and then restimulated T cells. For restimulation T 
cells were treated with anti-CD3/anti-CD28 antibodies. As compared to wild-type 
controls, Ezh2 deficient T cells displayed a 66.7% reduction in the level of phospho-
Erk1/2 two minutes after stimulation, (Figure 3.7B). Contrary to Erk phosphorylation, 
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Ezh2 deficiency did not lead to a defect in Akt phosphorylation (Figure 3.7B). 
Therefore, Ezh2 controls TCR-induced Erk phosphorylation in naïve as well as 
activated T cells. 
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Figure 3.7. TCR-induced Erk phoshporylation is impaired in the absence of 
Ezh2. A. TCR-induced phosphorylation of key signaling molecules were examined by 
Western blot analysis. Naïve CD4 T cells of indicated mutants were stimulated with 
anti-CD3/anti-CD28 antibodies, followed by cross-linking with secondary antibody. 
Ezh2-/- and PRC2-/- T cells showed reduced induction of Erk phosphorylation upon 
TCR stimulation. B. CD4 T cells from Ezh2 conditional knockout (CD4-Cre) mice 
and littermate controls were stimulated with PMA/Ionomycin for 2 days. The cells 
were rested one day, then, subjected to Erk phosphorylation assay, as described above. 
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3.6 PRC2 inhibitors suppress TCR-induced Erk phosphorylation 
The defect in TCR-induced Erk phosphorylation is likely not due to changes in 
gene expression, since we observed no changes in H3K27me3 and only minor changes 
in our RNA-seq; additionally the duration of the stimulation itself is too short to 
induce gene expression changes that could explain the defect. However, it could be 
argued that several minor changes, which were not detected with our genome-wide 
analysis, could play a role and the observed Erk defect reflects the indirect effects of 
such alterations. To address this issue, we utilized pharmacological inhibition of 
PRC2. We used GSK503, a selective and potent inhibitor of Ezh2. GSK503 is about 
200 fold selective over Ezh1 (Kiapp: 3nM for Ezh2 and 638nM for Ezh1, IC50 value: 
8nM for Ezh2 and 633nM for Ezh1) (Beguelin et al., 2013). GSK503 has favorable 
pharmacological kinetics in mice and therefore utilized for the in vivo experiments.  
To identify the best strategy for efficient inhibitor accumulation in T cells we 
compared several different pre-incubation and stimulation schemes and measured the 
intracellular concentration of GSK503 by mass spectrometry (Figure 3.8A). We 
confirmed that pre-incubation of cells on ice with GSK503 was as efficient as pre-
incubation at 37°C (Figure 3.8B). Pre-incubation increased the amount of intracellular 
GSK503 as compared to no pre-incubation plus inhibitor during the stimulation at 
37°C. Therefore, treatment of GSK503 on ice for 1hr was chosen to test the direct 
involvement of Ezh2 in TCR-induced Erk phosphorylation. We predicted that the pre-
incubation step on ice would minimize the possibility of transcriptional alterations 
during this period. We also measured the intracellular concentration after incubation 
of cells with 0 µM, 2 µM, 10 µM and 50 µM of GSK503 on ice for 1hr. We saw 
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similar levels of inhibitor influx for 2 and 10 µM GSK503, but drastically increased 
influx after incubation with 50 µM GDK503 (Figure 3.8C,D).  
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Figure 3.8. Intracellular concentration of GSK503 A. Experimental schemes for 
GSK503 treatment of CD4+ T cells. Colors indicate temperatures during incubation 
(Blue: 0°C, Red: 37°C). Condition 1: cells were pre-incubated with 2 µM of GSK503 
on ice for 1.25hr, followed by stimulating by TCR cross-linking at 37°C for 2 min. 
Condition 2: cells were pre-incubated and stimulated at 37°C. Condition 3: Cells were 
stimulated at 37°C for 2 min without pre-incubation. Condition 4: Cells were pre-
incubated on ice, but were not stimulated. B. Intracellular concentrations of GSK503 
after pre-incubation according to schemes described in A were measured by Mass 
spectrometry. C. Intracellular concentrations of GSK503 in the cells treated with 0 to 
50 µM of the inhibitors. D. Intracellular concentration of GSK503 is displayed as 
percent of the treatment concentration. Data represent mean ± standard deviation from 
three biological replicates (n=3). 
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Next, to test the hypothesis that Ezh2 directly controls TCR signaling, we 
assessed TCR-induced Erk phosphorylation in the presence of GSK503. While TCR 
engagement induces robust Erk phosphorylation in DMSO treated T cells, GSK503 
suppressed Erk phosphorylation in a dose dependent manner (Figure 3.9A). 
GSK600A, an inactive control compound for GSK503, did not exhibit the same effect, 
ensuring the specificity of GSK503 action on PRC2 in the inhibition of Erk 
phosphorylation (Figure 3.10). On the other hand, GSK503 treatment did not affect 
Erk phosphorylation induced by PMA, which directly activates PKC and RasGRP to 
activate Erk, circumventing proximal TCR signaling (Figure 3.9B). These results are 
in agreement with the finding that T cells do not require PRC2 for PMA/Ionomycin 
induced proliferation.  
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Figure 3.9. GSK503 suppresses TCR-induced Erk phosphorylation Purified CD4 
T cells were pre-incubated with 0, 2, 10 and 50 µM of GSK503 for 1hr on ice. Cells 
were stimulated by TCR cross-linking (A) or PMA (B) for 2 min and 10 min. 
Phospho-Erk1/2 (T202/Y204) and total Erk1/2 were detected by Western blot 
analysis. Relative level of Erk phosphorylation was quantified by comparing phospho-
Erk1/2 signal normalized to total Erk1/2 signal. Data are shown as mean ± standard 
deviation and is representative of at least three independent experiments. Student’s t-
test, *p<0.05, **p<0.01.  
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Figure 3.10. GSK600A does not inhibit TCR-induced Erk phosphorylation 
GSK600A, an inactive control compound for GSK503, was used to treat CD4+ T cells 
at 0 to 50 µM concentrations. Cells were stimulated by TCR cross-linking and Erk 
phosphorylation was examined. Data are shown mean ± standard deviation and 
representative of two independent experiments. 
 
 
We additionally confirmed the requirement of Ezh2 for TCR-mediated Erk 
activation with UNC1999, an independently developed inhibitor. UNC1999 inhibits 
both Ezh1 and Ezh2 and thereby we could achieve a clearer pharmacological 
inhibition of PRC2 (Konze et al., 2013). UNC1999 effectively abolishes TCR-induced 
Erk phosphorylation even at lower concentrations (Figure 3.11A). Treatment of 
UNC2400, an inactive control compound for UNC1999 showed no effect on Erk 
phosphorylation, confirming that PRC2 inhibition suppresses TCR-induced Erk 
phosphorylation (Figure 3.11B). Although we did not find an additive effect of 
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combined deficiency in Ezh1 and Ezh2 with respect to Erk phosphorylation, our data 
on TCR-induced proliferation strongly suggest that inhibition of both enzymes has a 
stronger impact on TCR signaling than Ezh2 deficiency alone. The fact that UNC1999 
was more effective, although we did not measure the intracellular concentration of 
UNC1999, and the fact that GSK503 completely inhibited Erk phosphorylation at a 
concentration that could also inhibit Ezh1, suggests that the same is also true for Erk 
activation.  
Collectively, these data provide direct evidence of control of TCR signaling by 
PRC2 independent of its role in histone modification. Pharmacological inhibition also 
indicates that the methyltransferase activity of Ezh2 is required for TCR-mediated Erk 
phosphorylation.  
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Figure 3.11. UNC1999, an independent Ezh2 inhibitor, efficiently blocks TCR-
induced Erk phosphorylation A. CD4+ T cells were treated with 0 to 10 µM of 
UNC1999, followed by TCR cross-linking. Levels of Erk phosphorylation were 
measured by Western blot analysis. Data are representative of two independent 
experiments. B. Cells were treated with 0 to 10 µM of UNC2400, a control compound 
for UNC1999, and TCR-induced Erk phosphorylation was measured. Data are 
representative of two independent experiments. 
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specific effect on Erk and not on any other induced modifications (Fig 3.7). To ensure 
that the defect in Erk phosphorylation after treatment with GSK503 is specific and not 
due to a general defect in the TCR induced signaling cascade we tested other TCR-
induced tyrosine phosphorylations. First we checked the overall pattern of tyrosine 
phosphorylation by Western blot analysis using a pan-anti-phospho-tyrosine antibody. 
There was no qualitative difference between DMSO treated cells and GSK503 treated 
cells (Figure 3.12A). This was even true at extremely high concentration of GSK503 
(100 µM). One of the key signaling proteins for TCR signal transduction is PLCγ1. 
DAG produced by PLCγ1 is a critical signaling intermediate for the Erk signaling 
pathway. Activation of PLCγ1 is regulated by tyrosine phosphorylation by Itk. 
Therefore, we checked if phosphorylation of PLCγ1 is affected by GSK503 treatment. 
Similar to genetic deletion of Ezh2, the pharmacological inhibition of Ezh2 by 
GSK503 did not influence the tyrosine phosphorylation of PLCγ1 (Figure 3.12B). In 
summary, Ezh2 inhibition does not alter TCR-induced tyrosine phosphorylation in 
general. Also, we conclude that GSK503 does not block the entire TCR signaling 
cascade, rather, it specifically regulates Erk phosphorylation.  
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Figure 3.12. GSK503 does not alter TCR-induced tyrosine phosphorylation. A. 
Purified CD4 T cells were pre-incubated with DMSO or a high concentration of 
GSK503, followed by TCR stimulation. Overall tyrosine phosphorylation events were 
examined by phospho-tyrosine Western blot. B. TCR-induced phospho-PLCγ1 levels 
in CD4 T cells treated with 0 to 50 µM of GSK503 were measured. Relative PLCγ1 
phosphorylation levels were obtained by normalizing phospho-PLCγ1 signal to total 
PLCγ1 signal. Data are shown mean ± standard deviation and representative of three 
(A) or two independent experiments (B). 
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3.8 Ezh2 controls TCR-mediated Erk phosphorylation in human T cells 
To address if the role of Ezh2 in signaling is conserved between human and 
mouse, we investigated the function of Ezh2 in TCR-induced Erk phosphorylation in 
human T cells. CD4 T cells were isolated from human blood and incubated with anti-
CD3 antibody (OKT3), followed by cross-linking. Compared to DMSO treated human 
CD4 T cells, GSK503 treated human CD4 T cells showed a reduced induction of Erk 
phosphorylation in a dose dependent manner (Figure 3.13A). Interestingly, this effect 
could be achieved even without pre-incubation with the inhibitor (Figure 3.13B). 
Although a direct comparison between GSK503 treatment in human and mouse T cells 
is difficult due to the difference in the source of the cells, it seems that human T cells 
are highly sensitive to GSK503. As seen in mouse T cells, human T cells could induce 
robust Erk phosphorylation upon PMA stimulation, which was not affected by 
GSK503 treatment (Figure 3.13C). Therefore, there is a common pathway between 
mouse and human for Ezh2 dependent TCR signaling. However, we observed almost 
no effect of the Ezh2 inhibitor in Jurkat cells (Data not shown). This suggests that 
perhaps a compensatory signaling pathway may exist in this leukemic cell line that 
bypasses the requirement of Ezh2 for TCR-induced Erk phosphorylation. In 
conclusion, Ezh2 methyltransferase activity is required for TCR-mediated Erk 
activation in human T cells. 
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Figure 3.13. GSK503 inhibits TCR-induced Erk phosphorylation in human T 
cells A. CD4 T cells were purified from human blood and pre-incubated with 
indicated concentration of GSK503 for 1 hr on ice. The cells were treated with mouse 
anti-human CD3 antibody (OKT3) for 15 min on ice, followed by cross-linking with 
secondary antibody at 37°C for 2 min. Phosphorylation of Erk was measured by 
Western blot and quantified for Erk induction. Phospho-Erk signal was normalized to 
total Erk signal and the fold-increase from 0 min to 2 min was calculated. B. Erk 
phosphorylation was examined with pre-incubation of 50 µM of GSK503 or without 
(50 µM of GSK503 was only present during stimulation). C. Human CD4 T cells were 
pre-incubated with GSK503 for 1 hr on ice, then, stimulated with PMA. PMA-induced 
Erk phosphorylation in the presence of indicated concentration of GSK503 was 
quantified. Data are shown mean ± standard deviation and representative of two 
independent experiments.  
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3.9 PRC2 controls antigen-specific T cell expansion in vivo 
We have shown that PRC2 directly regulates TCR signaling, particularly the 
TCR-induced Erk signaling pathway. Accordingly, TCR-mediated proliferation in 
vitro was impaired in the absence of PRC2. Therefore, we addressed the relevance of 
PRC2 function in in vivo T cell immunity. We first investigated the role of PRC2 in in 
vivo T cell activation by using the Lymphocytic choriomeningitis virus (LCMV) 
infection model. LCMV was first isolated from an infected monkey brain by Charles 
Armstrong. Later, Michael Oldstone and Rafi Ahmed obtained a variant of LCMV 
Armstrong from mouse spleen (Ahmed et al., 1984), called clone 13. Although they 
have the same immune-dominant epitopes such as GP33-41, GP276-286, NP396-404, and 
NP61-80, the two different strains bring about very different outcomes in terms of anti-
viral immune response in mice. LCMV Armstrong acutely infects mice and is cleared 
by CD8+ T cell mediated immune response. Clone 13 persistently infects mice and 
impairs CD8+ T cell functions. Therefore, this virus infection system can monitor the 
function of the same clonal population in a different infection setting. For this reason, 
the LCMV infection model has been extensively used for studying anti-viral T cell 
immunity and tolerance. The clearance of this virus is largely CD8+ T cell dependent. 
In addition to robust CD8+ T cell response, LCMV Armstrong also induces Th1 
responses. The peak of response is normally seen 8 days after infection. The kinetics 
of immune response is relatively consistent, clear and well characterized, making it an 
excellent tool to trace virus-specific T cells. Especially the immune response against 
the Armstrong strain infection exhibits the classical dynamics of a T cell response. 
65 	  
Therefore, we used the LCMV Armstrong acute infection model to understand the in 
vivo function of PRC2.  
We infected wild-type (Ezh2fl/fl, WT), Ezh1 knockout (Ezh1-/-, Ezh1 KO), 
Ezh2 conditional knockout (Ezh2fl/fl; CD4-Cre, Ezh2 cKO), and PRC2 knockout 
(Ezh1-/-Ezh2f/f;CD4-Cre, Ezh1/2 dKO) mice with LCMV Armstrong and utilized 
peptide-MHC class I tetramers to measure the number of virus-specific T cells. As 
expected, wild-type and Ezh1 knockout mice had a robust GP33-specific CD8+ T cell 
expansion at the effector phase (Figure 3.14A). Strikingly, this expansion was greatly 
diminished in Ezh2 conditional knockout and PRC2 knockout mice (Figure 3.14A). 
Not only CD8+ T cell that recognize GP33 epitope were impaired but also the GP276 
and NP396 specific T cells did not expand in the Ezh2 conditional knockout mice 
(Figure 3.14B). To check if Eed also plays an essential role in anti-viral immunity, we 
infected Eed conditional knockout (Eedfl/fl;CD4-Cre) mice with LCMV Armstrong. 
Indeed, Eed conditional knockout mice also fail to induce CD8+ T cell expansion 
(Figure 3.14C). These results were confirmed by examination of cytokine production 
of virus-specific T cells. The hallmark of the anti-viral CD8+ T cell response is the 
production of effector cytokines such as IFN-γ, TNF-α and IL-2 and Granzyme B. The 
production of these cytokines was severely hampered in ex vivo isolated CD8+ T cells 
from Ezh2 and Eed deficient mice (Figure 3.14D, E). The lack effector cytokine 
production is probably due to the lack of antigen-specific T cells. Additionally, 
Granzyme B expression was significantly reduced in Ezh2 and Eed deficient CD8+ T 
cells during infection (Data not shown). We also assessed CD4+ responses in terms of 
IFN-γ, TNF-α and IL-2 production. While CD4+ T cells from wild-type control mice 
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expressed these cytokines, Ezh2 and Eed deficient CD4+ T cells failed to produce 
them, indicating that antigen-specific CD4+ T cell expansion is also impaired in the 
absence of PRC2 (Figure 3.14F,G). These sets of data strongly indicate that PRC2 
plays an essential role in TCR-mediated T cell expansion in vivo.  
These results raised the question of at which stage of the immune response 
PRC2 is required for T cell expansion. Since PRC2 has been reported to play a role in 
the regulation of cell senescence (Kamminga et al., 2006), the greatly reduced number 
of antigen-specific T cells might be due to rapid cell death after an initial expansion in 
the early phase of the immune response. To check if PRC2 plays a role in early phase 
T cell expansion, we examined antigen-specific T cell frequencies at day 5 post-
infection, the earliest time point where we can detect a significant number of antigen 
specific viral tetramer positive cells. Interestingly, the numbers of tetramer positive T 
cells in Ezh2 conditional knockout mice and Eed conditional knockout mice were 
significantly lower than their wild-type control mice (Figure 3.15A,B). This suggests 
that the antigen-specific T cells never expanded. Moreover, the percentage of Ki-67 
positive cells among CD8+ T cell in Ezh2 conditional knockout mice was lower than 
in the wild-type mice (Figure 3.15C). These data show that PRC2 deficiency leads to a 
failure of TCR-mediated T cell proliferation in vivo. Next, we asked whether T cell 
proliferation is delayed or T cells are permanently unresponsive. We analyzed PBMC 
from wild-type and Ezh2 or Eed conditional knockout mice at day 5, 8 and 15 after 
infection. We measured the frequencies of GP33 specific T cells from individual mice 
at these time points. Until Day 8, compared to wild-type, Ezh2 conditional knockout 
mice exhibited much slower kinetics of GP33 specific T cell expansion, although both 
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groups show a similar pattern (Figure 3.15D). By day 15 wild-type T cells started to 
contract while Ezh2 deficient mice had large variations between them. In other words, 
some Ezh2 conditional knockout mice kept increasing in the frequency of GP33 
specific T cells while some of them showed contraction. Eed conditional knockout 
mice also had the similar phenotype (Figure 3.15E). However, the absolute number of 
antigen specific T cells in lymphoid organs and their functionality should be further 
addressed to pinpoint the real kinetics in immune responses. In conclusion, PRC2 
deficiency in T cells causes an early proliferation defect in vivo.  
Lastly, to confirm that the impaired immune response in the absence of PRC2 
correlates with failed virus clearance, we measured the virus titers from serum, spleen 
and lung of infected mice. Since we observed a failed induction of the anti-viral CD8+ 
T cell response, we speculated that the LCMV Armstrong infection would become a 
persistent infection in PRC2 deficient mice. In wild-type mice LCMV Armstrong is 
cleared by the immune system by day 8, and the virus titers are close to the detection 
limit. This was also the case for Ezh1 knockout mice (Figure 13.16A-D). In contrast, 
Ezh2 conditional knockout, Ezh1/2 double knockout mice, and Eed conditional 
knockout mice still had much higher titers in the serum and in several organs (Figure 
13.16A-D). Moreover, the virus was not cleared even 123 days after infection (Figure 
13.16E-F). Therefore, PRC2 deficient mice are incapable of clearing the normally 
acute LCMV Armstrong virus, resulting in a persistent infection. Collectively, PRC2 
is essential for anti-viral T cell immunity. 
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Figure 3.14. PRC2 plays an indispensable role in antigen-specific T cell 
expansion. A. DbGP33-41 positive T cells among splenic CD8+ T cells were stained 
with tetramer. The splenocytes were obtained from LCMV infected mice on the post-
infection day 8. The plots are gated on CD8+ T cells (left). The absolute numbers of 
GP33 specific CD8+ T cells from wild-type and indicated mutants were graphed 
(right). Data are shown as mean ± standard deviation and n=3-4 mice in each group B. 
The absolute number of GP33, GP276, and NP396 specific CD8+ T cells in spleens 
from wild-type mice and Ezh2 cKO mice on the post-infection day 8. N=5-6 mice in 
each group. Data are shown as mean ± standard deviation and representative of two 
independent experiments. C. The absolute numbers of splenic tetramer positive CD8+ 
T cells in Eed cKO and its wild-type control mice. N=3 mice in each group Data are 
shown as mean ± standard deviation and representative of three independent 
experiments. D-G. Flow cytometric analysis of cytokine production in CD4+ and 
CD8+ T cells. Splenocytes from wild-type control, Ezh2 cKO (D,F) and Eed cKO 
(E,G) mice on the post-infection day 8 were stimulated with GP33-41 peptides (D,E) 
and GP61-80 peptides (F,G) for 5hrs ex vivo. The stimulated cells were analyzed for 
IFN-γ, TNF-α and IL-2 by intracellular staining. The flow plots are gated on CD8+ 
(D,E) and CD4+ (F,G) and are representatives of three individual mice showing 
similar results. WT: Ezh2fl/fl or Eedfl/fl, Ezh1 KO: Ezh1-/-, Ezh2 cKO: Ezh2fl/fl; CD4-
Cre, Ezh1/2 dKO: Ezh1-/- Ezh2fl/fl; CD4-Cre. Student’s t-test, *p<0.05, **p<0.01, 
***p<0.001 
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Figure 3.15. PRC2 deficient T cells fail to proliferate at early stage of immune 
response. A,B. The numbers of tetramer positive T cells in spleens from wild-type 
and Ezh2 cKO mice (A) and Eed cKO (B) on post-infection day 5. N=3 or 2 mice per 
each group C. Percentage of Ki-67+ cells among splenic CD8+ T cells from wild-type 
and Ezh2 cKO mice on post-infection day 5. D,E. Kinetics of GP33 specific T cell 
frequency in PBMC of wild-type and Ezh2 cKO (D) or Eed cKO (E). Data from the 
same individual mice at different time points are connected with lines. Data are shown 
as mean ± standard deviation. Student’s t-test, *p<0.05, **p<0.01, ***p<0.001 
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Figure 3.16. PRC2 deficiency leads to persistent infection. (A-C). Virus titers on 
the post-infection day 8 were measured from spleen, serum, and lung. Spleen, serum, 
and lung were harvested from wild-type and indicated PRC2 mutants and 
homogenized to obtain virus, followed by performing plaque assay. The virus quantity 
was calculated by normalizing PFU to volume of serum or weight of organs. Log 10 
values of the normalized PFU/g or PFU/ml were plotted. N=3-4 mice per each group 
D. Virus titers in spleens of wild-type and Eed cKO mice on post-infection day 8. N=3 
per each group E,F. Serum virus titers of wild-type and Ezh2 cKO (E) and Eed cKO 
(F) was measured on post-infection day 15 and 123. N=7 or n=2 The crossline in each 
plot represents the detection limit of the plaque assay. Data are shown as mean ± 
standard error. 
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3.10 Suppression of T cell immunity by PRC2 inhibition 
Since we have shown that pharmacological inhibition of PRC2 prevented 
TCR-mediated Erk phosphorylation, we then attempted to use the inhibitor to 
modulate T cell immunity in vivo. We administrated 150 mg per kg of GSK503 
compound to C57BL/6 mice intra-peritoneally everyday starting on the day of the 
LCMV infection. On day 8-post infection, we sacrificed the mice to examine the 
frequencies antigen-specific T cells in the spleen. As predicted, virus infection induced 
splenomegaly in solvent treated group, and the number of CD4+ and CD8+ T cells as 
well as B cells were increased, compared to uninfected controls (Figure 3.17A). 
However in GSK503 treated mice the number of T and B cells did not increase (Figure 
3.17A). Importantly, there was no change in the number of B and T cells between 
solvent and GSK503 treated mice without infection, ruling out any possibility that 
toxicity of the inhibitor might have caused the decrease in cell numbers. When we 
analyzed the activation phenotypes in terms of CD44 and CD62L, the frequency and 
number of activated (CD44hi; CD62Llo) CD8+ T cells were significantly reduced upon 
GSK503 treatment during infection (Figure 3.17B). The percentage of activated cells 
among the CD4+ T cell population was only slightly reduced but the total number of 
activated CD4+ T cells was clearly decreased (Figure 3.17B). Therefore, overall T cell 
activation was diminished by GSK503 treatment. Importantly, the number of virus-
specific T cells were also significantly diminished, despite a large degree of variation 
in the GSK503 treated group (Figure 3.17C). The decreased number of virus-specific 
T cells and activated T cells correlated with increased virus titers in the GSK503 
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treated group (Figure 3.17D-F). In conclusion, pharmacological PRC2 inhibition 
suppresses antigen-specific T cell expansion in vivo.  
 
 
74 	  
	  
 
 
 
GP33 GP276 NP396
104
105
106
107
# 
Te
tr
am
er
+ 
C
D
8 
T 
ce
lls Solvent
GSK503
*** *** ***
CD4 CD8 B cell
100
101
102
103
104
105
106
107
108
# 
of
 c
el
ls
 p
er
 s
pl
ee
n
Uninfected / Solvent
Uninfected / GSK503
***
Infected / Solvent
Infected / GSK503
***
***
Solvent GSK503
0
1
2
3
4
5
6
7
Lo
g 
(P
FU
/g
)
Spleen
Solvent GSK503
0
1
2
2
3
4
5
6
7
Lo
g 
(P
FU
/g
)
Lung
Solvent GSK503
0
1
2
2
3
4
5
6
7
Lo
g 
(P
FU
/m
l)
Serum
A
B
C
D E F
CD4 CD8
0
20
40
60
80
100
%
C
D
44
+C
D
62
L-
 c
el
ls
***
n.s.
CD4 CD8
100
101
102
103
104
105
106
107
108
# 
C
D
44
+C
D
62
L-
 c
el
ls
Uninfected / Solvent
***
Infected / Solvent
Infected / GSK503
Uninfected / GSK503
***
75 	  
 
 
 
 
 	  	  
 
 
 
 
Figure 3.17. GSK503 inhibits T cell mediated anti-viral immunity. GSK503 and its 
solvent control were daily treated to C57BL/6 mice after LCMV Armstrong infection 
A. The number of splenic CD4+, CD8+ T and CD19+ B cells of GSK503 and its 
solvent control treated mice on the post-infection day 8 were plotted. B. The frequency 
(left) and the number (right) of CD44+CD62L- cells among CD4+ and CD8+ T cells are 
graphed. C. The number of DbGP33-41 tetramer positive CD8 T cells from spleens of 
GSK503 and solvent treated mice. N=4 mice per each group Data were shown as 
mean ± standard deviation D-F. Virus titers in spleen (D), lung (E) and serum (F) 
were measured by plaque assay. N=4 mice per each group Data were shown as mean ± 
standard error. Student’s t-test, *p<0.05, **p<0.01, ***p<0.001   	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3.11 Conclusion 
In this chapter, we discuss the role of PRC2 in TCR-mediated T cell activation 
by directly controlling TCR signaling. Using genetic models, which eliminate PRC2 
in peripheral T cells without having any gross developmental defect, we have shown 
the critical role of PRC2 for TCR-induced Erk phosphorylation and T cell 
proliferation. T cell proliferation was not affected by PRC2 deficiency when cells 
were stimulated with PMA/Ionomycin, which bypass the proximal signaling pathway. 
Importantly, the signaling defect we have seen in PRC2 deficient naïve T cells does 
not seem to be related to the nuclear function of PRC2. This conclusion is supported 
by the unaltered H3K27me3 level and gene expression in the absence of PRC2. 
However, arguments against using genetic model to prove the direct involvement of 
PRC2 in signaling are that PRC2 deficient T cell may have unknown developmental 
defects, or an accumulation of subtle gene expression changes that would not be 
detected in our statistical analysis. We addressed this issue by utilizing 
pharmacological inhibition of PRC2, providing direct proof for the direct contribution 
of PRC2-mediated lysine methylation to signal transduction. Indeed, Ezh2 inhibitors 
could suppress TCR-induced Erk phosphorylation. The inhibitor did not suppress 
PMA-induced Erk phosphorylation, consistent with our earlier finding that PMA-
induced T cell proliferation does not require PRC2. Also, control compounds and 
unaffected general tyrosine phosphorylation downstream of the TCR support the 
specificity of PRC2 inhibitors in TCR-induced Erk phosphorylation. Finally, we show 
the relevance of PRC2 in T cell activation in vivo. Using acute an infection model, 
PRC2 deficiency and inhibition severely compromised T cell immunity. 
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CHAPTER 4: IDENTIFICATION OF A CYTOSOLIC SUBSTRATE OF EZH2 
AND THE FUNCTION OF EZH2-MEDIATED LYSINE METHYLATION 
4.1 The PRC2 complex exists in the cytosol 
The suppression of TCR-induced Erk phosphorylation by inhibition of PRC2 
in wild-type T cells strongly indicates a function of PRC2 in cytosolic signaling. 
Therefore, in this chapter, we hypothesize that PRC2 exists in the cytosol, contains the 
core components essential for methyltransferase activity and cytosol-specific 
components, which integrate PRC2 into TCR signaling. We primarily investigate the 
cytosolic PRC2 (cPRC2) with regard to its cytosolic interaction partners and complex 
composition. We performed nuclear and cytosolic fractionations of T cells and 
performed Western blot analysis for known PRC2 components. Previous studies have 
shown that nuclear PRC2 consists of at least four core components including Ezh2 (or 
Ezh1), Eed, Suz12 and RbAp48. AEBP2 was also identified in the initial complex 
purification from the Yi Zhang lab, and Jarid2 was later discovered as an additional 
component of PRC2. Our Western blot analysis shows that the nuclear PRC2 
components, Ezh1, Ezh2, Suz12, Eed and RbAp48 are also expressed in cytosol of 
both naïve and activated T cells (Figure 4.1A). Jarid2 expression is upregulated in 
activated T cells as previously reported (Pereira et al., 2014) and it was readily 
detected in the cytosol of activated T cells. The amounts of Ezh2, Jarid2 and Suz12 
also significantly increased while the expression of Ezh1, Eed and RbAp48 were 
unchanged or only moderately increased in the cytosol (Figure 4.1A). Although we 
did not directly quantify the amounts of Ezh1 and Ezh2 in the cytosol, given the strong 
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upregulation of Ezh2 after activation, it is plausible that in activated T cells most 
cPRC2s contains Ezh2 as its methyltransferase subunit. Additionally although the 
PRC2 complex is often described as a nuclear complex it is important to consider the 
following information. The Western blot data presented here were generated by 
loading equal amounts of total protein lysate from each fraction (Figure 4.1A). 
Cytosolic fractions from activated T cells have approximately three times more protein 
than cytosolic fractions from naïve T cells. Therefore, taking into account the increase 
of cellular contents in the cytosol of activated T cell, the absolute amount of cytosolic 
Ezh2 is higher than nuclear Ezh2. Next, we tested whether these components form a 
complex in the cytosol by performing Ezh2 co-immunoprecipitations. Indeed, all 
known core components including Suz12, Eed, Jarid2, and RbAp48 could be co- 
immunoprecipitated with Ezh2 from cytoslic fractions (Figure 4.1B,C). Interestingly 
we also found Ezh1 was interacting with Ezh2. The classical view is that individual 
PRC2 complexes contain either Ezh1 or Ezh2. Our data suggest that Ezh1-PRC2 and 
Ezh2-PRC2 interact or a novel PRC2 complex might be envisioned that contains both 
enzymes. In addition, our data confirm the previously published data that cPRC2 has 
enzymatic activity like the nuclear complex since all the components necessary for 
histone methyltransferase activity are present (Su et al., 2005). 
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Figure 4.1. PRC2 is present in the cytosol. A. Western blot analysis for Ezh1, Ezh2, 
Suz12, Eed, Jarid2 and RbAp48 of cytosolic/nuclear fractions of naïve and activated T 
cells. To obtain activated T cells, purified CD4+ T cells were stimulated on plate-
bound anti-CD3/anti-CD28 antibodies for 3 days. Lamin B and Tubulin were used as 
fractionation and loading controls. B,C. Co-immunoprecipitation assay with Ezh2. 
Ezh2 was immunoprecipitated from cytosolic/nuclear fractions of naïve and activated 
T cells and analyzed for co-immunoprecipitation of Ezh1, Ezh2, Eed, Suz12, Jarid2 
and RbAp48. Tubulin, Lamin B and H3 were used as fractionation controls.  
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cytosolic interaction partners of Ezh2. As described earlier, Ezh2 was discovered in 
mammals as an interaction partner of Vav1 (Hobert et al., 1996). In addition to Vav1, 
we also studied the possible interaction between Nck proteins and Ezh2. Nck1 and its 
homolog Nck2, hereafter referred to as Nck since our analysis does not distinguish 
between Nck1 and Nck2 in Western blot, are signaling adaptor molecules that have 
more than 60 interaction partners (Lettau et al., 2010). Nck deficiency phenocopies 
Ezh2 deficiency in TCR-induced Erk phosphorylation and actin polymerization in 
MEFs and T cells (Roy et al., 2010). Interestingly, Nck deficient T cells have a 
selective defect in Erk signaling pathway but intact JNK and Akt activation, 
something we also observed in Ezh2 deficient T cells. Therefore, we hypothesize that 
Nck is a possible link between cPRC2 and the TCR signaling cascade. To test this 
hypothesis, we immunoprecipitated Nck from the cytosol of cells that received TCR 
stimulation for 0 to 30 min, followed by Western blot analysis for Vav1 and Ezh2. As 
our hypothesis predicted, Nck was constitutively associated with Ezh2 and Vav1 
(Figure 4.2A). We also detected Suz12 in Nck immunoprecipitates, indicating that the 
interaction is with cPRC2 and not free Ezh2 (Data not shown). To test the quality of 
the interaction between Ezh2, Nck and Vav1, we performed washes of the IPed 
material with increasing amounts of salt. Ezh2, Nck and Vav1 form a stable complex, 
resistant to even 600mM NaCl (Figure 4.2B,C). These data support two arguments: 1) 
cPRC2 is physically coupled to the TCR signaling cascade via interaction with Vav1 
and Nck and 2) cPRC2 may be functionally relevant for TCR signaling. Therefore, it 
would be interesting to investigate the functional outcome of the disruption of this 
complex. ?
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Figure 4.2. Vav1, Nck and Ezh2 form a stable complex in the cytosol. A. Nck co-
immunoprecipitation in unstimulated/stimulated Jurkat cell lysates. Duration of 
stimulation with anti-human CD3 antibody (OKT3) is indicated. The co-
immunoprecipitates were analyzed for Ezh2, Vav1 and Nck. B. Vav1 was 
immunoprecipitated from purified murine CD4+ T cells. The co-immunoprecipitates 
were incubated with 150, 300 and 600 mM of NaCl containing wash buffer to remove 
weak interactions. The co-immunoprecipitates were analyzed for Ezh2, Vav1 and Nck. 
C. Nck co-immunoprecipitates from purified murine CD4+ T cells were incubated 
with 150, 300 and 600 mM of NaCl containing wash buffer, followed by Western blot 
analysis for Ezh2, Vav1 and Nck. ?
 
4.3 Nck is required for Vav1/Ezh2 association 
Next, we closely examined the Nck/Vav1/Ezh2 complex. We wanted to 
address the contribution of Nck to the interaction between Vav1 and Ezh2. Therefore 
we immunoprecipitated Vav1 from an Nck1/2 knockdown Jurkat cell line and probed 
A
Input IP: Nck
0 2 5 10 30 0 2 5 10 30IgG
Ezh2
TCR stimulation 
(min):
Vav1
Nck
Tubulin
B
IgG 150 300 600
IP: Nck
NaCl (mM)
Ezh2
Vav
Nck
Input IgG 150 300 600
IP: Vav
NaCl (mM)
Ezh2
Vav
Nck
C
82 	  
by Western blot for the presence of Ezh2. The ShRNA knockdown resulted in ~70% 
reduction in protein levels of Nck1/2. Surprisingly, shRNA-mediated knockdown of 
Nck led to reduced interaction between Ezh2 and Vav1 (Figure 4.3). Therefore, Nck is 
important for Vav1/Ezh2 association. The interaction between Ezh2 and Vav1 seems 
to be constitutive and independent of TCR engagement confirming the previous 
published observation (Su et al., 2005). TCR stimulation did not increase or decrease 
the reduction in interaction between Vav1 and Ezh2. Therefore, Nck contribution to 
the interaction between Ezh2 and Vav1 was not increased or decreased upon TCR 
stimulation (Figure 4.3), indicating that TCR stimulation does not facilitate or 
diminish this interaction.  
 
	  
Figure 4.3. Nck is required for Vav1/Ezh2 association. Wild-type Jurkat cells and 
shRNA-mediated Nck1/2 knockdown cells were stimulated with anti-human CD3 
antibody (OKT3). Vav1 was immunoprecipitated from cytosolic cell lysates and the 
co-immunoprecipitates were analyzed for Ezh2 by Western blot. Nck Western blot 
was done to show the knockdown. Data are representative of two independent 
experiments. 
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4.4 Ezh2 is associated with the TCR 
We have explored the composition of cPRC2 and found that two critical 
components of TCR signaling pathway are associated with Ezh2, Vav1 and Nck. Vav1 
is a known interaction partner of Zap70 (Katzav et al., 1994), a kinase that binds to 
phosphorylated ITAM motifs in the cytoplasmic tails of the TCR. Nck also directly 
interacts with the TCR, namely with the proline rich region of CD3ε (Gil et al., 2002). 
Therefore, we hypothesized that Ezh2 may be associated with TCR. To test this 
hypothesis, we to pulled down the TCR and associated proteins by two different 
methods. First, we pulled down the TCR complex by first incubating the cells with 
anti-CD3/anti-CD28 antibodies, crosslinking of the TCR with biotin-conjugated 
secondary antibody and ultimately pulling down the bound complexes with 
streptavidin coated magnetic beads. As a control, we performed the same pull downs 
from unstimulated cells but with a minor modification. We incubated the cells with the 
same antibodies as for the stimulated cells, however, we incubated the cells for a 
longer period on ice and instead of allowing the secondary antibodies to bind to the 
primary antibodies at 37°C, which would induce the TCR signaling cascade, we also 
incubated with the secondary antibody on ice. Interestingly, the TCR pull down from 
unstimulated and stimulated cells both contained Ezh2 (Figure 4.4A). When we 
normalized the amount of proteins pulled down to amount of CD3ε pull down, we 
found that the association between Ezh2 and TCR was increased by 1.57 fold upon 
TCR stimulation. Also, Vav1 inducibly associated with TCR (2.54 fold increase after 
stimulation). Ezh2 was not found in unbiotinylated secondary antibody treated cells, 
meaning that Ezh2 was specifically pulled down with TCR bound to biotin-conjugated 
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antibody (Figure 4.4A). As stimulation control, we confirmed that Erk 
phosphorylation was induced in stimulated cells. For the interaction of Nck with TCR, 
the result looks somewhat complicated since we did not observe any induction upon 
stimulation (1.04 fold increased after stimulation). The incubation with secondary 
antibody on ice might still trigger conformational changes of the TCR and expose Nck 
binding sites although this treatment prevents TCR-induced phosphorylation events. In 
support of this hypothesis is a report that showed that the interaction between Nck and 
CD3ε was increased upon TCR engagement even in the presence of the Src-kinase 
inhibitor PP2 (Paensuwan et al., 2016). The second method we employed to test the 
interaction between Ezh2 and TCR was reciprocal immunoprecipitation of Ezh2 and 
CD3ε, followed by western blot detection of Ezh2 and CD3ε. We confirmed the 
association of Ezh2 and CD3ε in both unstimulated and stimulated T cells (Figure 
4.4B). The interaction seems to be increased upon stimulation. These data show that 
the cPRC2 complex directly interacts with CD3ε and is well localized to influence the 
TCR signaling pathway.  
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Figure 4.4. Ezh2 is associated with TCR. A. Streptavidin pull-down of biotinylated 
secondary antibody bound to anti-CD3/anti-CD28 antibodies. Purified CD4+ T cells 
were treated with anti-CD3/anti-CD28 antibodies for 15 min on ice, followed by 
incubation with biotinylated or unbiotinylated secondary antibodies on ice for 15 min 
(unstimulated) or at 37°C for 2 min (stimulated). The pull-down was analyzed for 
Ezh2, CD3ε, Vav1, Nck and Suz12 by Western blot. Phospho-Erk and total Erk was 
blotted as TCR stimulation control. B. Co-immunoprecipitation of Ezh2 and CD3ε 
from unstimulated and TCR-stimulated T cells. Co-immunoprecipitates were 
immunoblotted for Ezh2 and CD3ε.  
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4.5 Conclusion 
Here we showed that the PRC2 complex is present in the cytosol of human and 
mouse T cells and that it is associated with Nck and Vav1. These cytosol specific 
components seem to connect cPRC2 directly to the TCR. Moreover, Ezh2 indirectly or 
directly is associated with the TCR. This finding implies three things. The fact that 
cPRC2 contains the core components of the nuclear PRC2 suggests it has 
methyltransferase activity. Indeed, we already found evidence that the 
methyltransferase activity of cPRC2 is necessary to allow full Erk phosphorylation 
after TCR crosslinking in the previous chapter, provided by the PRC2 inhibitor 
experiments. Second, cPRC2 is constitutively associated with its cytosolic interaction 
partners. These interactions might retain cPRC2 in the cytoplasm, which otherwise 
might be translocated to nucleus due to its NLS sequence. In agreement with this 
observation, the dramatic increase in the amount of cPRC2 in the cytosol of activated 
T cells could be explained by the increased expression of Vav1 in stimulated cells. 
The larger cytosolic proportion of the PRC2 complex might also be important for 
proper gene regulation, since an overabundance of PRC2 in the nucleus could lead to 
an overly repressive epigenetic environment. Lastly, the interaction between Ezh2 and 
CD3ε of the TCR explains why PRC2 deficiency specifically disrupts proximal TCR 
signaling. In summary, we show that a cytosolic PRC2 complex exists and that it 
interacts with central components of TCR signaling.  
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CHAPTER 5: IDENTIFICATION OF AN EZH2 SUBSTRATE AND THE 
FUNCTION OF EZH2-MEDIATED LYSINE METHYLATION 
5.1 Identification of histone-like sequences in Vav1 interaction partners 
To ascertain the importance of cPRC2 for signaling, it became necessary to 
understand the precise mechanisms. In the previous chapters we identified strong 
evidence that cPRC2 methyltransferase activity is required for TCR-induced Erk 
phosphorylation and that cPRC2 contains the essential components for this activity. 
Therefore, it is likely that Ezh2-mediated lysine methylation governs the function of 
cPRC2. In this chapter, we attempt to identify cytosolic substrates of Ezh2.  
To identify cytosolic substrates of Ezh2, we utilized an in silico screen for 
target consensus sequences among Vav1 interacting proteins. As mentioned above, a 
histone-like sequence can help to identify protein sequences that can be methylated by 
histone methyltransferases. Our laboratory was successful before in identifying non-
histone substrates of G9a/GLP with this approach (Sampath et al., 2007). Here we 
tried to identify sequences encompassing the target lysine residues that can be 
methylated by Ezh2. Vav1 is a functional and direct interaction partner of Ezh2 with a 
known role as adapter protein therefore we tried to find the Ezh2-target sequence 
among Vav1 interacting proteins (Figure 5.1A). We identified a histone-like sequence 
in the linker region between the first and second SH3 domain of Nck1 (Figure 5.1B). 
As shown in the figure, the amino acid sequence surrounding lysine 64 of Nck1 is 
highly similar to the sequences of histone 3 lysine 27, which is the methylation site for 
Ezh2.    
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Nck exists as two homologs, Nck1 and Nck2, which have 76% sequence 
homology. The proteins contain three SH3 domains, which can bind to proline rich 
region and one SH2 domain that can recognize phosphorylated tyrosines (Pawson, 
1994; Pawson and Gish, 1992). Most sequence variation between Nck1 and Nck2 
reside in the linker regions, whose function is not well studied. These structural 
features enable the Nck proteins to serve as signaling adaptor molecules by linking 
tyrosine phosphorylation on one protein to various downstream proteins containing 
proline rich regions. In particular, Nck is required for TCR-induced Erk 
phosphorylation, although the exact mechanism is not known (Roy et al., 2010). A 
well-known function of Nck is the recruitment of actin polymerizing protein WASP to 
TCR signaling cluster (Zeng et al., 2003). In MEFs, PDGF-induced actin 
polymerization is also dependent on Nck proteins (Bladt et al., 2003). Since Nck 
controls Erk signaling pathway in T cells and actin polymerization pathway in MEFs, 
and the same pathways are affected in Ezh2 deficient T cells and MEFs, respectively 
(Ref), it is conceivable that Ezh2 and Nck function in the same pathway. Therefore, 
we hypothesize that Nck1 is a cytosolic substrate of Ezh2.  
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Figure 5.1. Nck1 contains a histone-like sequence. A. In silico search for Ezh2 
target consensus sequences among Vav1 interacting proteins. Seven sequences from 
known targets of Ezh2 were aligned to Vav interacting proteins. Nck1 was identified 
to have a histone-like sequence. B. Histone-like sequence in Nck1. Nck1 has a 
histone-like sequence in a linker region between the first and second SH3 domain. 
Sequence similarity to the histone 3 sequence was labeled with red and the lysine 
residue that can be methylated by Ezh2 was colored in blue.  
 
5.2 Nck1 is methylated by Ezh2 
To directly test whether Ezh2 methylates the cytosolic protein Nck1, we 
performed in vitro methyltransferase assays with recombinant PRC2. In this assay, we 
used His tagged Nck1 as a substrate and recombinant PRC2 containing Ezh2, Eed, 
Suz12, RbAp48 and AEBP2. We traced the methylation by using 3H-SAM as methyl-
donor and detected the methylated proteins by auto-radiography. Our results show that 
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PRC2 can directly methylate Nck1 protein in vitro (Figure 5.2A). We also confirmed 
by Mass Spectrometry that in vitro methylated Nck1 contains methyl-lysine residues 
(Figure 5.2B). Indeed, the methylation site was the site we had predicted in our in 
silico target screen.  
	  
Figure 5.2. Ezh2 methylates Nck1 A. In vitro methyltransferase assay was performed 
using 3H-SAM. Recombinant PRC2 was incubated with recombinant his-tagged Nck1 
for 1.5 hr at 30°C. Histone 3.1 was used as positive control. Autoradiography (left) 
and coomassie staining (right) are shown. B. Nck1 protein from in vitro 
methyltransferase assay was subjected to mass spectrometric analysis. LC-MS/MS 
spectra of Nck1 is displayed.  
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Next, we sought to confirm that the methylation also occurs in vivo. We 
immunoprecipitated Nck1 from cytosolic lysates of unstimulated and TCR-stimulated 
Jurkats, followed by probing for lysine methylation using an anti-pan methyl lysine 
antibody. The ability of antibody to detect methylated Nck was confirmed by Western 
blot of in vitro methylated Nck (Figure 5.3A). As shown, PRC2 mediated methylation 
of Nck1 was detected by the pan-methyl lysine antibody. Furthermore, we detected the 
methylation in Nck pulled down from Jurkat cell lysates, suggesting that Ezh2-
medated Nck methylation is present in Jurkat cells, independent of activation of the 
cells (Figure 5.3B).  
 
	  
Figure 5.3. Nck is methylated in T cells. A. Westernblot analysis on recombinant 
Nck1 protein methylated in vitro using a pan-methyl lysine antibody. B. Lysates from 
unstimulated Jurkat cells or cells stimulated with anti-human CD3 antibody (OKT3) 
for 2 min was used for Nck immunoprecipitation. The immunoprecipitates were 
probed for Nck and pan-methyl-lysine.  
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5.3 Ezh2 methylates a lysine residue in a histone-like sequence 
To confirm the identified methylation site, we performed methyltransferase 
assays with Nck158-81 peptides containing amino acid substitutions. We designed Nck1 
peptides aligned to the histone-like sequence. Then, we also designed K-to-R or K-to-
A substituted peptides to test the contribution of each lysine to the methylation signal. 
As predicted, substitution of lysine 64 to either arginine or alanine substantially 
abolished the methylation signal (Figure 5.4). We also observed methylation on lysine 
59, although the degree of methylation was lower than for lysine 64. By comparing the 
substitutions of K-to-R and K-to-A substitutions of lysine 59 indicated that structural 
factors might regulate the methylation of lysine 64. In other words, while K-to-R 
substitution of lysine 59 did not affect the methylation of lysine 64, the K-to-A 
substitution reduced the methylation of lysine 64. When we introduce substitution to 
both lysines, we could completely remove the methylation signal, indicatinging that 
PRC2 methylation is specific towards lysine residues and not arginine. Also, no other 
lysines in the region could be methylated in vitro. Therefore, these data strongly 
support our hypothesis that Ezh2 methylates the histone-like sequence of Nck1.  
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Figure 5.4. Lysine 64 of Nck1 is methylated by Ezh2 In vitro methyltransferase 
assay was performed with Nck158-81 peptides. Nck1 peptides were designed as shown. 
Amino acid substitutions are depicted in red and indicated in the column substitutions. 
Band intensities from autoradiography were quantified and displayed in the right 
column. Relative values were indicated (+ < 0.25, ++ < 0.5, +++ < 0.75, ++++ >0.75 
to wild-type peptide).   
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methylation of Nck1 by cPRC2. We hypothesized that the Nck containing PRC2 
complex has methyltransferase activity and can methylate Nck. To test this hypothesis, 
first, we examined if Nck interacting proteins have methyltransferase activity on 
histones. We immunoprecipitated Nck and used the co-immunoprecipitating cPRC2 
complex as enzyme in an in vitro histone methyltransferase assay. As positive control, 
we immunoprecipitated Ezh2 from the cytoplasm and used it as enzyme for the 
reaction. Our data show that co-immunoprecipitates of Nck and Ezh2 can methylate 
Nck1 (Figure 5.5). Therefore, Nck interacts with a histone methyltransferases, 
presumably Ezh2. 
We next asked if Nck interacting proteins could methylate Nck1. For this, we 
used the same experimental scheme as in Figure 5.5 but utilized recombinant His-
tagged Nck1 protein as a substrate instead of H3.1. Interestingly, we found that co-
immunoprecipitates of Nck could methylate Nck1 itself, suggesting that Nck can be 
methylated by its interaction partners (Figure 5.6). We could also detect co-
immunoprecipitation of Ezh2 with Nck. Therefore, these data show that a Nck 
containing methyltransferase complex can methylate Nck1 and that the cPRC2 
complex co-immunoprecipitates with Nck. But these data cannot exclude the presence 
of an additional methyltransferase. Therefore we performed the methyltransferase 
assay in the presence of the Ezh2 inhibitor GSK343. The methylation signal was 
significantly reduced, but not completely abolished (Data not shown). This indicates 
either the presence of an additional enzyme capable to methylate Nck1 or the 
incomplete inhibition of Ezh2. We have not attempted to control for the second 
possibility since we are unsure about the affinity of the PRC2 complex to different 
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substrates. We have preliminary data that an Ezh1 containing PRC2 complex can also 
methylate Nck peptide. Therefore, the incomplete blockade of Nck1 methylation by 
GSK343 may be due the lower activity of this inhibitor towards Ezh1, which is 
another component of cPRC2 (Figure 4.1B).  
 
96 	  
	  
Figure 5.5. Nck interacting proteins contain histone methyltransferase activity. 
Jurkat cell lysates were incubated with rabbit IgG, anti-Nck antibody, or anti-Ezh2 
antibody for co-immunoprecipitations. The co-immunoprecipitates were used for in 
vitro methyltransferase assay with H3.1 and 3H-SAM.  
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Figure 5.6. Nck interacting proteins methylate Nck1. A. Nck1 was 
immunoprecipitated from Jurkat cell lysates, followed by in vitro methyltransferase 
assay with the co-immunoprecipitated product, recombinant His-Nck1 protein and 3H-
SAM. His-Nck1 is indicated on the autoradiography (left) and the coomassie staining 
(right). B. Co-immunoprecipitation of Ezh2 with Nck.  
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5.5 Self-methylation of Ezh2 
One consistent observation we made in the methyltransferase assays was the 
Ezh2 self-methylation (Figure 5.2B). The band corresponding to Ezh2 was heavily 
methylated in the reaction. This led us to investigate the self-methylation of Ezh2 
since Ezh2 itself is another cytosolic substrate. For a cleaner system of Ezh2 self-
methylation, we performed in vitro methyltransferase assays in the absence of other 
substrates, followed by mass spectrometric analysis. We observed that Ezh2 is 
methylated after an in vitro reaction (Figure 5.7A). When this reaction product was 
subjected to mass spectrometric analysis, we found that lysine 735 was mono-
methylated (Figure 5.7B). This lysine is located at C-terminal region of Ezh2, right 
next to SET domain (Figure 5.7C). To exclude an in vitro artifact we decided to check 
for Ezh2 self-methylation in vivo. When we pulled down Ezh2 from stimulated T cells 
and analyzed it by mass spectrometry, we found the same site was methylated in vivo, 
suggesting that Ezh2 methylation may be physiologically important. Whether the 
methylation is stimulus-dependent or not is worthwhile to be further investigated. 
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Figure 5.7. Ezh2 is self-methylated. A. Autoradiography of in vitro 
methyltransferase assay on Ezh2. B. Mass spectrometric analysis of in vitro 
methylated Ezh2. C. Domain structure of Ezh2 and methylation site. Lysine 735 
(indicated with red arrow) at the C-terminal region of Ezh2 was methylated. D. CD4+ 
T cells were stimulated with anti-CD3/CD28 antibodies. The lysates were incubated 
with anti-Ezh2 antibody to pull down Ezh2 and the immunoprecipitated Ezh2 were 
subjected to mass spectrometric analysis. 
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5.6 PRC2-mediated lysine methylation modulates protein-protein interaction 
The final question in this study is to determine the function of Ezh2-mediated 
methylation. In this study, we identified two substrates of Ezh2. Interestingly, Jarid2, 
another PRC2 component, is also methylated by Ezh2 (Sanulli et al., 2015). Therefore, 
there are three proteins associated with cPRC2 that are targets of Ezh2. Given that 
methylation can play a role in the modulation of protein-protein interactions, these 
methylation targets might potentially serve as docking sites for other proteins. If this is 
the case, Ezh2-mediated methylation would contribute to the formation of a large 
signaling complex. Our hypothesis is that PRC2-mediated methylation of its 
components and other cytosolic substrates facilitates protein recruitment. To validate 
this hypothesis, we examined the interactome of Nck and Ezh2 in the 
presence/absence of Ezh2-mediated methylation. For this approach we utilized 
proteomic analysis of immunoprecipitated material from untreated or Ezh2 inhibitor 
treated cells.  
We treated murine CD4 T cells with GSK503 following the previous 
experimental scheme, which inhibits TCR-induced Erk phosphorylation. We 
immunoprecipitated Nck or Ezh2 from the TCR-stimulated cells, followed by 
identification of co-immunoprecipitated proteins. Then, we identified the proteins that 
were less enriched in Nck-IP upon GSK503 treatment. We found that 71 proteins were 
specifically enriched after Nck-IP over control IgG-IP. The co-immunoprecipitation 
with Nck of 6 proteins was lost after GSK503 treatment and are therefore most likely 
dependent on Ezh2-mediated methylation (Figure 5.8). On the other hand the co-
immunoprecipitation of 2 proteins increased in the GSK503 treated samples, 
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indicating that the recruitment of some proteins is inhibited by Ezh2-mediated 
methylation. 
 
	  
Figure 5.8. Interactome of Nck changes upon GSK503 treatment Purified murine 
CD4+ T cells were pre-incubated with DMSO or GSK503 for 1hr on ice, followed by 
TCR cross-linking for 2 min at 37°C. Nck co-immunoprecipitation was performed and 
eluted samples were subjected to mass spectrometry. Each dot represents the 
normalized log2 value of peptide abundance in Nck-IP/IgG-IP from DMSO treated 
cells (y-axis) and Nck-IP from DMSO treated cells/Nck IP from GSK503 treated cells 
(x-axis). Bright area indicates proteins enriched in Nck IP. Ribosomal proteins and 
keratins were removed from the list.  
  
Additionally, we performed the same analysis on the Ezh2 interactome. In this 
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immunoprecipitation contained Ezh1, Ezh2, Suz12, Eed, RbAp46/48, AEBP2, Jarid2, 
and MTF2 (Figure 5.9). The abundance of these proteins in the Ezh2 
immunoprecipitation was not altered, neither upon stimulation nor GSK503 treatment. 
Therefore, Ezh2-mediated lysine methylation does not modulate the core complex 
composition.  
	  
 
Figure 5.9. Ezh2 interactome in T cells modulated by Ezh2 inhibition. Mass 
spectrometric analysis of Ezh2 interaction partners in unstimulated and stimulated T 
cells in the presence/absence of GSK503. GSK503 or DMSO treated cells were 
stimulated with TCR for 2 min. Co-immunoprecipitation of Ezh2 was analyzed. The 
protein list was filtered by IgG immunoprecipitation control, followed by removal of 
ribosomal proteins and keratins. Each dot represents the normalized log2 value of 
peptide abundance in Ezh2 IP from DMSO treated stimulated cells/GSK503 treated 
stimulated cells (y-axis) and Ezh2 IP from DMSO treated stimulated cells/DMSO 
treated unstimulated cells (x-axis).  
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Table 5.1. List of proteins that interact with Ezh2 upon TCR stimulation but lose 
interaction in the presence of GSK503 
 
 
Interestingly, CD3 and LCP2 (Slp76) were associated with Ezh2 in T cells, 
confirming our previous finding that Ezh2 is associated with the TCR complex. Our 
analysis identified 46 proteins that had increased interaction with Ezh2 after 
stimulation and 14 out of 46 proteins had decreased interaction in the presence of 
GSK503 (Figure 5.9 and Table 5.1). Collectively, these data suggest that Ezh2-
mediated lysine methylation modulates TCR-dependent interaction with cPRC2. Also, 
together with Nck methylation, multiple methylation sites render cPRC2 into a 
signaling scaffold to assemble a macromolecular complex (Figure 5.10). Once 
GSK503 inhibits methylation, the complex is no longer properly assembled and 
signaling is defective.  
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Figure 5.10. Model of the function of cPRC2 in protein complex formation cPRC2 
contains multiple lysine residues, including Nck K64, Ezh2 K735 and Jarid2 K116, 
which can undergo methylation. Ezh2-mediated methylation is important for the 
recruitment of multiple biding partners to assemble signaling complex. Ezh2 inhibition 
blocks the generation of docking sites, thereby, impairs the complex formation. 	  
Lastly, we also attempted to address the contribution of Vav1 to the Ezh2 
interactome upon TCR stimulation. Interaction between Vav1 and Ezh2 has implicated 
for its functional importance in Talin1 methylation in dendritic cells (Gunawan et al., 
2015). The proposed mechanism of methylation states that Vav1 recruits Ezh2 to its 
substrates. Therefore, for some substrates, Vav1 deficiency would lead to the loss of 
methylation, mimicking Ezh2 inhibition, resulting in the loss of interaction with 
cPRC2. We hypothesized that Vav1 deficiency may alter the Ezh2 interactome after 
TCR stimulation. To examine the Ezh2 interactome in Vav1 deficient T cells, we used 
the J.Vav Jurkat cell line, which lacks Vav1. First, we confirm that the cPRC2 
complex in Jurkat cells contains all the previously identified components including 
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Ezh1, Ezh2, Suz12, Eed, RbAp46/48, AEBP2, Jarid2, and MTF2 (Figure 5.11). In 
Jurkat cells, we could identify two more complex components, are PHF1 and PHF19. 
247 proteins were enriched in Nck-IP from unstimulated cells. Among those, 28 
proteins had increased interactions with Ezh2 and 27 proteins had reduced 
interactions. When we analyzed the whole list, 44 proteins interact with Ezh2 upon 
stimulation in wild-type Jurkat cells. By comparing proteins that increase their 
association with Ezh2 after TCR stimulation in wild-type Jurkat cells but not Vav1 
deficient Jurkat we were able to identify proteins whose interaction is TCR-induced 
and controlled by Vav1. 28 proteins met these criteria (Table 5.2). This list includes 
several cytoskeleton-related proteins such CKAP2L and tropomyosin, confirming that 
Ezh2 is involved in cytoskeleton remodeling in the context of interaction with Vav1. 
Notably, one of the key cell death molecules, BID was associated with Ezh2 upon 
stimulation only in wild-type cell. This may explain how Ezh2 regulates cell survival 
in tumor cells. Also, interaction with the important TCR signaling molecule 
calreticulin with Ezh2 is increased upon stimulation in wild-type Jurkat while the 
interaction was not induced in Vav1 KO cells. In summary, these data show that the 
TCR dependent Ezh2 interactome is regulated by Vav1.	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Figure 5.11. The Ezh2 interactome is modulated by Vav1 deficiency upon TCR 
stimulation Ezh2 was pulled down from wild-type Jurkat cells (WT) and the Vav1 
deficient Jurkat cell line J.vav (KO), followed by mass spectrometric analysis of 
interaction partners. Each dot represents the normalized log2 value of the peptide 
abundance in Ezh2 IP from stimulated wild-type Jurkat cells/unstimulated wild-type 
Jurkat cells (y-axis) and Ezh2 IP from stimulated J.Vav cells/unstimulated J.Vav cells 
(x-axis). The bright area indicates proteins increased in wild-type cells after 
stimulation but unchanged in J.Vav cells upon stimulation. IgG IP was used for 
filtering parameter and ribosomal proteins and keratins were removed from the list.  	  
One of the striking things we found here was that Ezh2 IP from any of the 
Jurkat samples contained Ezh1 whereas all the samples for primary CD4 T cells did 
have Ezh1 in the list of proteins interacting with Ezh2. Perhaps, this observation 
implies that there is a different function of Ezh1-PRC2 in Jurkat cells than in primary 
T cells. For example, in primary T cells, Ezh1-PRC2 and Ezh2-PRC2 may exist in a 
dimer while Jurkat cells have separate Ezh1-PRC2 and Ezh2-PRC2 complexes. The 
functional difference of these complexes will be worthwhile studying. 
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Table 5.2. List of proteins with increased interaction with Ezh2 in wild-type cells 
after TCR stimulation but unchanged interaction with Ezh2 in J.Vav cells 
 
 
Lastly, we found that both unstimulated and stimulated Vav1 deficient cells 
lacked the association between Ezh2 and CD3ε. These data strongly suggest that Vav1 
regulates the association of Ezh2 with the TCR. 
 
5.7 Conclusions 
In this chapter, we mainly discussed the mechanistic perspectives of cPRC2 in 
T cells. We identified two novel substrates, Nck1 and Ezh2, and their methylation 
sites. In addition, we showed that Nck interacting proteins contain methyltransferase 
activity. Our proteomic analysis suggests that Ezh2-mediated lysine methylation 
modulates protein-protein interactions and inhibition of methyltransferase activity 
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during TCR stimulation alters the interactome of its substrates. Although we proved 
many aspects of the function of Ezh2-mediated methylation, it might be interesting to 
test the biological consequence of mutating those lysine residues.  
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CHAPTER 6: DISCUSSION 
In this study, we have explored the cytosolic role of PRC2 in TCR-mediated T 
cell activation. We showed that PRC2 plays an essential role in TCR-mediated T cell 
proliferation. In our PRC2 deficient mouse model, peripheral T cells retain wild-type 
levels of histone modifications and normal gene expression. However, PRC2 deficient 
T cells showed a signaling defect, independent of its function on histone modification, 
underscoring the direct impact of PRC2 in signaling events. This observation was 
substantiated by the use of pharmacological inhibitors of PRC2 targeting its catalytic 
activity. In addition, we found that cPRC2 was composed of known core components 
and identified cytosolic interaction partners such as Nck1 and Vav1. Importantly, 
Ezh2 was associated with the TCR, indicating the direct role of PRC2 for TCR-
induced signaling events. In order to understand the molecular mechanism of cPRC2 
function in signaling, we relied on proteomic analysis to identify interacting partners 
in the cytosol as well as the ability of cPRC2 to methylate substrates. We found that 
cPRC2 function in signaling was mediated by the methylation of its cytosolic 
substrate, Nck1. Along with Nck1, Ezh2 was self-methylated and these multiple 
methylation events may regulate protein-protein interactions during stimulation. In 
conclusion, cPRC2-mediated lysine methylation modulates signaling in T cells by 
regulating the interactions between Nck1 and Ezh2. We envision a model where 
cPRC2 may form a macromolecular signaling complex that depends on lysine 
methylation.  
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6.1 PRC2 controls T cell proliferation through cytosolic signaling  
We showed that genetic ablation or pharmacological inhibition of PRC2 
activity leads to a severe defect in T cell proliferation. Several in vitro and in vivo 
studies have shown that deletion of Ezh2 causes a reduction in the number of effector 
T cells and fail to expand in long-term cultures (Yang et al., 2015; Zhang et al., 2014). 
These reports related the lack of T cell expansion to gene dysregulation by the 
impairment of PRC2-mediated H3K27me3. In contrast, we show that the impaired 
proliferation is due to defective signaling. Indeed, we also observed that induction of 
H3K4 tri-methylation in several genes was significantly reduced in PRC2-deficient T 
cell upon TCR stimulation. However, H3K4 tri-methylation is not governed by 
nuclear function of PRC2. Therefore, we concluded that failure of H3K4 tri-
methylation induction is due to reduction in signaling capacity. The genes that had the 
most significant reduction in H3K4 tri-methylation level include Il2 and Il2rα, which 
are highly relevant to T cell proliferation and survival.  
We found that PRC2 deficient T cells had the defective induction of Erk 
phosphorylation upon TCR stimulation. Since Erk signaling is important for T cell 
proliferation (D'Souza et al., 2008), the impaired Erk signaling may explain the 
proliferation defect in PRC2 deficient T cells. Regarding the defect in TCR-induced 
Erk phosphorylation, one can argue that PRC2 deficient T cells had the 
developmentally accumulated defect related to Erk activation. Most importantly, we 
came up with the key argument by using pharmacological inhibitor. Using 
pharmacological inhibitors ruled out the possible contribution of developmentally 
accumulated effect to the signaling defect we have seen. Moreover, PMA-induced 
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signaling was not impaired in the presence of the PRC2 inhibitor, strongly pointing 
out that PRC2 is involved in specific signaling pathway. Also, the fact that PRC2 
deficiency and PRC2 inhibitors did not affect tyrosine phosphorylation events further 
excluded the potential non-specific behavior of the inhibitor on TCR signaling. All of 
these evidences suggest that PRC2 plays an essential role in TCR-mediated T cell 
proliferation by directly controlling signaling pathway. The further study to connect 
Erk signaling defect to failure of in vivo T cell expansion in PRC2 deficient mice 
requires us to examine the levels of Erk phosphorylation in T cell population.  
 
6.2 Placement of PRC2 in TCR-induced Erk signaling pathway 
TCR signaling pathway strongly activates the Erk pathway. PRC2 inhibition 
did not disrupted PLCγ1 phosphorylation, indicating it controls signaling downstream 
of PLCγ1. Intact PMA-induced Erk phosphorylation in the inhibitor treated cells 
further narrows down the potential position of PRC2 in Erk signaling pathway. 
However, since PLCγ1 is the enzyme responsible for DAG production, which PMA 
mimics, selective defect from PRC2 deficiency can be only explained by tyrosine 
phosphorylation independent regulation of PLCγ1 activity by PRC2 or PLCγ1-
independent signaling pathway. Another possibility is that PKC fails to be recruited to 
the plasma membrane bound signaling cluster in PRC2 deficient T cells. Therefore, 
localized DAG production at the plasma membrane could not activate PKC but PMA 
treatment could overcome this lack of PKC activation. Assuming that cPRC2 and Vav 
are on the same pathway, cPRC2 may control membrane translocation of PKC through 
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Vav-mediated PKC translocation (Villalba et al., 2002; Villalba et al., 2000). When 
we examined the TCR-induced actin polymerization pathway that was controlled by 
Ezh2, Ezh2 plays a role upstream of Cdc42, but downstream of Vav tyrosine 
phosphorylation (Su et al., 2005). As mentioned earlier, Vav is immediately upstream 
of cdc42, therefore, there also must be an alternative regulatory function of Ezh2 that 
controls the enzymatic function of Vav independent of tyrosine phosphorylation. To 
dissect this model, it is necessary to examine the composition of the TCR signaling 
complex and localization of signaling mediators in the context of PRC2 deficient T 
cells. 
 
6.3 Contribution of Ezh1 and Ezh2 to T cell immunity 
Our in vitro and in vivo data had some discrepancy with regards to the T cell 
proliferation phenotype. Ezh2 KO T cells did not exhibit a defect in proliferation upon 
TCR stimulation in vitro while there was almost no expansion of antigen-specific T 
cells in Ezh2 knockout mice. Two lines of evidence can explain the contradicting 
results. First, the Ezh2 KO itself has defect in actin dynamics in vivo (Gunawan et al., 
2015; Su et al., 2005), which can be overcomed by stimulation with anti-CD3/anti-
CD28 antibodies. Our previous publication demonstrated that Ezh2 deficient T cells 
had a defect in APC:T cell conjugate formation. T cell :APC engagement would not be 
affected by PRC2 deficiency in a system using anti-CD3/anti-CD28 antibodies. To test 
this possibility, we imaged transgenic T cells with labeled OT-II transferred into 
RAG-/- mice, followed by immunization. Second, Ezh2 plays an unique role in 
113 	  
controlling death molecules while the signaling defect is only seen in the total absence 
of both Ezh1 and Ezh2. To validate whether the lack of effector T cells in vivo in the 
EZH2 KO mice can be attributed to cell death or a lack of proliferation, we transferred 
CFSE-labeled Ezh2 deficient T cells into RAG-/- and challenged the recipient mice 
with antigens. Probably, due to existence of the redundant enzyme, Ezh1, the 
phenotype is sensitive to concentration of stimuli and age of the mice that were used. 
Once both enzymes are ablated, the phenotype becomes more apparent regardless of 
other variables. A certain degree of redundancy of Ezh1 and Ezh2 in signaling is also 
further confirmed by Eed deficiency, which has a proliferation defect in vitro. 
Moreover, we have seen more dramatic reduction in TCR-induced Erk 
phosphorylation by treating GSK503 at the concentration that inhibits Ezh1. 
Therefore, Ezh1 as well as Ezh2 contribute to signaling. 
We showed that Ezh2 up-regulation is much higher than Ezh1 in activated T 
cells. Although we could not quantify the absolute amount of Ezh1 and Ezh2 in T 
cells, it can be assumed that cells are differentially utilizing Ezh1 and Ezh2 based on 
activation status. For example, in resting T cells, Ezh1 plays a significant role in 
signaling while Ezh2 takes on the dominant role in activated T cells. An earlier report 
showing the interaction between Ezh1 and ZAP70 (Ogawa et al., 2003), highlights the 
signaling involvement of Ezh1. Therefore, both Ezh1 and Ezh2 seem to be involved in 
cytosolic signaling. However, distinct features of Ezh1 and Ezh2 enzymatic activity 
were reported. For histone, Ezh1 methyltransferase activity is lower than Ezh2 
(Margueron et al., 2008). Therefore, one speculation is that activated T cells use Ezh2-
PRC2 predominantly, presumably due to the requirement for the higher enzymatic 
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activity in the activated T cells. We do not know whether this is true for cytosolic 
substrates but it is likely that such switch system presents in cells. Also, this 
hypothetical model can explain the different outcomes from Ezh2 deficiency and 
Ezh1/2 deficiency. In other words, long-term culture In vitro or an in vivo situation 
that drives sustained proliferation with rapid expansion. In these situations, Ezh2 may 
become absolute requirements since cells would be largely relying on Ezh2-mediated 
cell proliferation rather than utilizing both enzymes. 
 
6.4 Localization of PRC2 in cytosol 
We have shown that Ezh2 is associated with TCR in this study. Ezh2 also 
interacts with the TCR signaling components Nck and Vav1. We also have shown in 
this study that Nck is required for optimal interaction between Ezh2 and Vav. 
Interestingly, Ezh2 association with CD3ε disappeared in Vav deficient cells, based on 
our mass spectrometric analysis. These pieces of data indicate that Ezh2 is localized 
with the TCR signaling cluster, through Nck that directly interacts with CD3ε and the 
Nck interacting protein Vav (Pauker and Barda-Saad, 2011; Santiveri et al., 2009). 
Therefore, it would be interesting if we find co-localization of those three proteins in T 
cells. To get more understanding how PRC2 is localized to TCR and signaling 
clusters, it may be necessary to monitor dynamic movement of Ezh2 by imaging 
techniques. Upon TCR stimulation, TCR initially forms microclusters. Whether PRC2 
is included in the microcluster will bolster our argument that PRC2 directly controls 
TCR signaling in cytosol. Also, if we figure out which area of immunological synapse, 
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for instance, central supermolecular activation cluster (cSMAC) and peripheral SMAC 
(pSMAC), Ezh2 is localized to after TCR stimulation, we would be able to elucidate 
the detailed and specific role of PRC2 in actin skeleton remodeling and TCR 
signaling. Our preliminary results generated by immunofluorescence show that Ezh2 
forms foci rather than diffused in cytosol of activated T cells. If it is reproducible, it 
strongly suggests that Ezh2 also gets into TCR microclusters and actively transduce 
the signaling.  
 
6.5 Vav/Nck/Ezh2 complex formation  
We have shown that Nck is required for optimal interaction between Vav1 and 
Ezh2 by co-immunoprecipitation experiments using shRNA-mediated knockdown 
cells lines. Two possible models exist to explain this result. The first model is that the 
interaction of Nck with Vav1 or Ezh2 facilitates/stabilize the interaction between Ezh2 
and Vav1. Therefore, in this model, it is likely that Vav1, Nck and Ezh2 cooperatively 
interact with each other to form a trimeric complex. The second model is that the 
interaction between Vav1 and Ezh2 is indirect and bridged by Nck. In Nck 
knockdown cell line, the interaction is reduced but not abolished. Therefore, Nck most 
likely only stabilizes the interaction between Vav1 and Ezh2. But since the 
knockdown efficiency is not 100%, it is still possible that the remaining Nck can 
facilitate the interaction. A genetic deletion analysis can address this issue for sure. 
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6.6 Methylation of cytosolic substrates by PRC2 
In our study, we put large efforts into the identification of cPRC2 substrates. 
We approached this using a candidate-based screening methodology. However, there 
are several unbiased screening methods for identifying methyltransferase substrates. 
Also, currently, lysine methylome is actively investigated and it is more obvious that 
many cellular proteins as well as histone proteins are methylated. One of techniques 
for approaching this problem is in vitro methyltransferase assay with protein arrays 
(Levy et al., 2011b). This method can give us lists of proteins directly methylated by 
PRC2. However, often protein arrays do not include all the proteins (>9000 proteins) 
and high chance to miss the real targets. Also, if the methyltransferase used in the 
assay is not specific but quite promiscuous, the result may not be recapitulated in vivo. 
For directly approaching to in vivo substrates of PRC2, we could pan-methyl lysine 
specific antibody to enrich the methylated proteins, followed by mass spectrometric 
analysis (Cao et al., 2013). However, there is weakness here as well since more 
abundant methylated proteins will be detected and less abundant methylated proteins 
will be missed. Therefore, filtering step is required to reduce mass spectrometric bias. 
Perhaps, crosslinking immunoprecipitation of Ezh2 may be helpful for this approach. 
Also, development of better pan-methyl lysine antibodies is required. We could not 
provide the stimulus dependent methylation in this study. In Jurkat cells, Nck proteins 
seem to be methylated even before stimulation. This result may explain why we could 
not inhibit TCR-induced Erk phosphorylation with the Ezh2 inhibitor in Jurkat cells. 
Moreover, taking account into low level of methylation in general, we need to develop 
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better tools to detect methylated Nck in primary T cells. For this purpose, it is 
necessary to develop anti-methyl Nck antibody.  
 
6.7 Lysine methylation for signaling complex assembly 
Our hypothesis is that Ezh2-mediated lysine methylation provides binding 
modules to cytosolic PRC2 itself to assemble the signaling complex. Indeed, protein-
protein interactions related to Nck and Ezh2 were altered by inhibition of Ezh2. It 
would be interesting if we identify the exact binding partners of the methyl-lysines in 
Nck and Ezh2. To do so, we can design peptide interaction assays with unmethylated 
peptides and methylated peptides. For instance, we could incubate T cell lysates with 
Nck1 K64me1 and K64me0 peptides and examine which proteins come with each 
peptide, and compare the list. In this way, we would be able to find novel methyl 
binding proteins.  
Our hypothetical model favors TCR-induced lysine methylation and TCR-
dependent assembly of a signaling complex controlled by the methylation. The 
question is how to combine two elements above. The possible mechanism of TCR-
dependent assembly of a large signaling complex by PRC2-mediated methylation is 
the post-translational modification of PRC2 by phosphorylation. The interaction 
between ZAP-70 and Ezh1 is regulated by phosphorylation of Ezh1 by Lck (Ogawa et 
al., 2003). This study shows that TCR-dependent signaling pathway actually 
assembles a signaling complex with PRC2. Additionally, the phosphorylation of Ezh2 
was shown to regulate its methyltransferase activity (Cha et al., 2005; Kaneko et al., 
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2010; Kim et al., 2013). These studies collectively point out that the activity and 
interaction with signaling molecules of PRC2 can be regulated by signal-dependent 
phosphorylation events. Therefore, in our study, phosphorylation of PRC2 
components upon TCR stimulation may enhance methylation of its substrates as well 
as binding to TCR signaling complex.  
This study focuses on a novel signaling paradigm that relies on lysine 
methylation for signaling. Discovery of demethylase (Shi et al., 2004) implicates that 
lysine methylation may be highly dynamic. Interestingly, our proteomic analysis of 
Ezh2-IP reveals that LSD1 is associated with Ezh2 before and after TCR stimulation 
(Figure 5.9 and 5.11). It suggests the possible demethylation on Ezh2 and its targets. 
Therefore, lysine methyltransferase activity and demethylase activity of PRC2-
associated complex may be regulated by stimulation. It is of interest to figure out the 
dynamics of lysine methylation and address whether there is a turn-off system like 
phosphatases in phosphorylation cascades although finding demethylases is extremely 
hard. Our data suggest that initiation of TCR-induced lysine methylation is at least 
earlier than threonine phosphorylation of Erk, while we do not have any clue for the 
duration of lysine methylation. Dissection of dynamics of signal-induced lysine 
methylation will shed light on many aspects of lysine methylation in signaling. 
   
6.8 Involvement of PRC2 in receptor signaling other than TCR signaling 
One of the exceptional questions regarding signaling involvement of PRC2 is 
whether Ezh2 controls signaling downstream of a broad range of cell surface receptors 
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or specifically of TCR. Previously, several reports suggest that Ezh2 controls non-
TCR receptor-mediated signaling events. For example, Ezh2 plays a crucial role in 
PDGF-induced actin polymerization in MEFs (Su et al., 2005). Also, there was a 
report showing the reduced FGFR-mediated Erk phosphorylation in Ezh2-deficient ES 
cells (Tee et al., 2014). Also, it was shown that Ezh2 regulates an integrin-mediated 
signaling pathway in actin dynamics (Gunawan et al., 2015). Therefore, it seems that 
the control of receptor-mediated signaling by Ezh2 is universal biological process, 
rather than the TCR specific phenomenon. As T cell proliferation and survival is also 
regulated by various cytokine signaling such as IL-2, IL-7 and IL-15, it is of interest to 
dissect the contribution of PRC2 to cytokine signaling pathways. Particularly, in in 
vivo autoimmune setting, where cytokines are also largely responsible for T cell 
expansion, it is possible that loss of Ezh2 leads to amelioration in T cell mediated 
autoimmune syndrome. In addition to autoimmune settings, T cell driven intestinal 
inflammation is depending on cytokines as well as microbiome-specific TCR. 
Therefore, to understand the precise mechanisms by which PRC2 controls T cell 
immunity in vivo, it is essential to address the potential involvement of PRC2 in 
cytokine signaling pathways.  
In this regard, the role of PRC2 in memory T cell response is also an 
interesting subject. Memory T cells are maintained largely by cytokines. Interestingly, 
Ezh2 was shown to be important for STAT3 signaling, which can be activated by 
various cytokines (2013; Dasgupta et al., 2015; Kim et al., 2013). Of note, IL-21-IL-
10-STAT3 signaling axis plays a pivotal role in maintenance of memory T cells (Cui 
et al., 2011). To test the impact of PRC2 on memory T cells, we should be able to 
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control the timing of Ezh2 inhibition. It can be achieved by utilizing either Cre-ERT2 
driven deletion of Ezh2 or pharmacological inhibitions of Ezh2. In summary, studying 
the role of PRC2 in regulation of cytokine signaling pathways or other receptor 
signaling pathways will further deepen our understanding of actions of PRC2 in vivo. 
Also, it will help us to develop the therapeutic strategies for treating autoimmune 
syndromes or adverse effects from anti-tumor immunotherapy with Ezh2 inhibitors.  
 
6.9 Therapeutic implications of PRC2 inhibition 
Our work unveiled a novel role of PRC2 in T cell immunity and given that 
PRC2 activity can be modulated with small molecules, it is an attractive candidate for 
therapeutic treatment to ameliorate T cell mediated pathogenesis. Indeed, we 
generated data that Ezh2 inhibition is effective in the treatment of autoimmunity. We 
tested the therapeutic efficacy of PRC2 inhibition in two different pathological 
settings, regulatory T cell (Treg) depletion induced inflammation and experimental 
autoimmune encephalomyelitis (EAE). We depleted Tregs using the previously 
described FoxpDTR mice with the use of diphtheria toxin which resulted in 
lymphoproliferative disease (Kim et al., 2007). We treated GSK503 to Treg depleted 
mice for two weeks and observed that the autoimmune syndrome characterized by 
lymphadenopathy and splenomegaly disappeared upon GSK503 treatement. Similarly, 
the symptoms of EAE mice were ameliorated by GSK503 treatment. We treated mice 
with GSK503 after EAE induction. Compared to solvent treated mice, GSK503 treated 
mice showed significantly alleviated disease progression. Interestingly, resting cells 
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were not affected by the drug administration. These data strongly indicate the potential 
usage of PRC2 inhibitors in stopping unwanted inflammation. In this sense, Ezh2 
inhibitors could be used as a drug to treat the autoimmune side effect from immune 
checkpoint blockade (Weber et al., 2012). However, the timing and specificity of the 
therapeutic strategies should be considered carefully so that patients would be still 
benefit from checkpoint blockade without any immunocompromised disease.  
Mechanistically, one of the main caveats of in vivo experiments using the Ezh2 
inhibitor was that it is difficult to distinguish between the impact of Ezh2 inhibition on 
T cells and other immune cell subsets such as dendritic cells. To bolster our arguments 
that Ezh2 inhibitors dampened immune responses mainly by controlling T cell 
expansion, we could treat T cell specific Ezh2 conditional knockout mice with Ezh2 
inhibitors for in vivo experiments. Then, we can score an additional effect on immune 
responses, presumably non-T cell subsets, although T cell specific deletion is already 
dramatically reduced the degree of T cell responses in virus infection models and 
autoimmune models. By precisely understanding the contribution of the inhibitor to T 
cell immunity, we could better assess the inhibitor as a therapeutic tool for T cell-
mediated autoimmune syndromes.  
 
 
 
 
122 	  
BIBLIOGRAPHY 
 
(2013). Methylation by EZH2 activates STAT3 in glioblastoma. Cancer discovery 3, 
OF21. 
Agger, K., Cloos, P.A., Christensen, J., Pasini, D., Rose, S., Rappsilber, J., Issaeva, I., 
Canaani, E., Salcini, A.E., and Helin, K. (2007). UTX and JMJD3 are histone H3K27 
demethylases involved in HOX gene regulation and development. Nature 449, 731-
734. 
Aghazadeh, B., Lowry, W.E., Huang, X.Y., and Rosen, M.K. (2000). Structural basis 
for relief of autoinhibition of the Dbl homology domain of proto-oncogene Vav by 
tyrosine phosphorylation. Cell 102, 625-633. 
Ahmed, R., Salmi, A., Butler, L.D., Chiller, J.M., and Oldstone, M.B. (1984). 
Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of 
persistently infected mice. Role in suppression of cytotoxic T lymphocyte response 
and viral persistence. The Journal of experimental medicine 160, 521-540. 
Alberola-Ila, J., Forbush, K.A., Seger, R., Krebs, E.G., and Perlmutter, R.M. (1995). 
Selective requirement for MAP kinase activation in thymocyte differentiation. Nature 
373, 620-623. 
Ambler, R.P., and Rees, M.W. (1959). Epsilon-N-Methyl-lysine in bacterial flagellar 
protein. Nature 184, 56-57. 
Anjum, R., and Blenis, J. (2008). The RSK family of kinases: emerging roles in 
cellular signalling. Nature reviews Molecular cell biology 9, 747-758. 
Arvey, A., van der Veeken, J., Samstein, R.M., Feng, Y., Stamatoyannopoulos, J.A., 
and Rudensky, A.Y. (2014). Inflammation-induced repression of chromatin bound by 
the transcription factor Foxp3 in regulatory T cells. Nature immunology 15, 580-587. 
Baier-Bitterlich, G., Uberall, F., Bauer, B., Fresser, F., Wachter, H., Grunicke, H., 
Utermann, G., Altman, A., and Baier, G. (1996). Protein kinase C-theta isoenzyme 
selective stimulation of the transcription factor complex AP-1 in T lymphocytes. 
Molecular and cellular biology 16, 1842-1850. 
Barber, E.K., Dasgupta, J.D., Schlossman, S.F., Trevillyan, J.M., and Rudd, C.E. 
(1989). The CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p56lck) 
that phosphorylates the CD3 complex. Proceedings of the National Academy of 
Sciences of the United States of America 86, 3277-3281. 
123 	  
Barski, A., Cuddapah, S., Cui, K., Roh, T.Y., Schones, D.E., Wang, Z., Wei, G., 
Chepelev, I., and Zhao, K. (2007). High-resolution profiling of histone methylations in 
the human genome. Cell 129, 823-837. 
Beguelin, W., Popovic, R., Teater, M., Jiang, Y., Bunting, K.L., Rosen, M., Shen, H., 
Yang, S.N., Wang, L., Ezponda, T., et al. (2013). EZH2 is required for germinal 
center formation and somatic EZH2 mutations promote lymphoid transformation. 
Cancer cell 23, 677-692. 
Bi, K., Tanaka, Y., Coudronniere, N., Sugie, K., Hong, S., van Stipdonk, M.J., and 
Altman, A. (2001). Antigen-induced translocation of PKC-theta to membrane rafts is 
required for T cell activation. Nature immunology 2, 556-563. 
Bladt, F., Aippersbach, E., Gelkop, S., Strasser, G.A., Nash, P., Tafuri, A., Gertler, 
F.B., and Pawson, T. (2003). The murine Nck SH2/SH3 adaptors are important for the 
development of mesoderm-derived embryonic structures and for regulating the cellular 
actin network. Molecular and cellular biology 23, 4586-4597. 
Bubeck Wardenburg, J., Pappu, R., Bu, J.Y., Mayer, B., Chernoff, J., Straus, D., and 
Chan, A.C. (1998). Regulation of PAK activation and the T cell cytoskeleton by the 
linker protein SLP-76. Immunity 9, 607-616. 
Bunnell, S.C., Diehn, M., Yaffe, M.B., Findell, P.R., Cantley, L.C., and Berg, L.J. 
(2000). Biochemical interactions integrating Itk with the T cell receptor-initiated 
signaling cascade. The Journal of biological chemistry 275, 2219-2230. 
Bustelo, X.R. (2000). Regulatory and signaling properties of the Vav family. 
Molecular and cellular biology 20, 1461-1477. 
Bustelo, X.R. (2001). Vav proteins, adaptors and cell signaling. Oncogene 20, 6372-
6381. 
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, 
R.S., and Zhang, Y. (2002a). Role of histone H3 lysine 27 methylation in Polycomb-
group silencing. Science 298, 1039-1043. 
Cao, X.J., Arnaudo, A.M., and Garcia, B.A. (2013). Large-scale global identification 
of protein lysine methylation in vivo. Epigenetics 8, 477-485. 
Cao, Y., Janssen, E.M., Duncan, A.W., Altman, A., Billadeau, D.D., and Abraham, 
R.T. (2002b). Pleiotropic defects in TCR signaling in a Vav-1-null Jurkat T-cell line. 
The EMBO journal 21, 4809-4819. 
Cha, T.L., Zhou, B.P., Xia, W., Wu, Y., Yang, C.C., Chen, C.T., Ping, B., Otte, A.P., 
and Hung, M.C. (2005). Akt-mediated phosphorylation of EZH2 suppresses 
methylation of lysine 27 in histone H3. Science 310, 306-310. 
124 	  
Chan, A.C., Irving, B.A., Fraser, J.D., and Weiss, A. (1991). The zeta chain is 
associated with a tyrosine kinase and upon T-cell antigen receptor stimulation 
associates with ZAP-70, a 70-kDa tyrosine phosphoprotein. Proceedings of the 
National Academy of Sciences of the United States of America 88, 9166-9170. 
Chan, A.C., Iwashima, M., Turck, C.W., and Weiss, A. (1992). ZAP-70: a 70 kd 
protein-tyrosine kinase that associates with the TCR zeta chain. Cell 71, 649-662. 
Cho, H.S., Hayami, S., Toyokawa, G., Maejima, K., Yamane, Y., Suzuki, T., Dohmae, 
N., Kogure, M., Kang, D., Neal, D.E., et al. (2012). RB1 methylation by SMYD2 
enhances cell cycle progression through an increase of RB1 phosphorylation. 
Neoplasia 14, 476-486. 
Chuikov, S., Kurash, J.K., Wilson, J.R., Xiao, B., Justin, N., Ivanov, G.S., McKinney, 
K., Tempst, P., Prives, C., Gamblin, S.J., et al. (2004). Regulation of p53 activity 
through lysine methylation. Nature 432, 353-360. 
Clipstone, N.A., and Crabtree, G.R. (1992). Identification of calcineurin as a key 
signalling enzyme in T-lymphocyte activation. Nature 357, 695-697. 
Costello, P.S., Walters, A.E., Mee, P.J., Turner, M., Reynolds, L.F., Prisco, A., Sarner, 
N., Zamoyska, R., and Tybulewicz, V.L. (1999). The Rho-family GTP exchange 
factor Vav is a critical transducer of T cell receptor signals to the calcium, ERK, and 
NF-kappaB pathways. Proceedings of the National Academy of Sciences of the United 
States of America 96, 3035-3040. 
Cui, W., Liu, Y., Weinstein, J.S., Craft, J., and Kaech, S.M. (2011). An interleukin-21-
interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ 
T cells. Immunity 35, 792-805. 
D'Souza, W.N., Chang, C.F., Fischer, A.M., Li, M., and Hedrick, S.M. (2008). The 
Erk2 MAPK regulates CD8 T cell proliferation and survival. J Immunol 181, 7617-
7629. 
Dasgupta, M., Dermawan, J.K., Willard, B., and Stark, G.R. (2015). STAT3-driven 
transcription depends upon the dimethylation of K49 by EZH2. Proceedings of the 
National Academy of Sciences of the United States of America 112, 3985-3990. 
Deak, M., Clifton, A.D., Lucocq, L.M., and Alessi, D.R. (1998). Mitogen- and stress-
activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, 
and may mediate activation of CREB. The EMBO journal 17, 4426-4441. 
Dillon, S.C., Zhang, X., Trievel, R.C., and Cheng, X. (2005). The SET-domain protein 
superfamily: protein lysine methyltransferases. Genome biology 6, 227. 
Dobenecker, M.W., Kim, J.K., Marcello, J., Fang, T.C., Prinjha, R., Bosselut, R., and 
Tarakhovsky, A. (2015). Coupling of T cell receptor specificity to natural killer T cell 
125 	  
development by bivalent histone H3 methylation. The Journal of experimental 
medicine 212, 297-306. 
Downward, J., Graves, J.D., Warne, P.H., Rayter, S., and Cantrell, D.A. (1990). 
Stimulation of p21ras upon T-cell activation. Nature 346, 719-723. 
DuPage, M., Chopra, G., Quiros, J., Rosenthal, W.L., Morar, M.M., Holohan, D., 
Zhang, R., Turka, L., Marson, A., and Bluestone, J.A. (2015). The chromatin-
modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity 
after activation. Immunity 42, 227-238. 
Ebinu, J.O., Bottorff, D.A., Chan, E.Y., Stang, S.L., Dunn, R.J., and Stone, J.C. 
(1998). RasGRP, a Ras guanyl nucleotide- releasing protein with calcium- and 
diacylglycerol-binding motifs. Science 280, 1082-1086. 
Eissenberg, J.C., Morris, G.D., Reuter, G., and Hartnett, T. (1992). The 
heterochromatin-associated protein HP-1 is an essential protein in Drosophila with 
dosage-dependent effects on position-effect variegation. Genetics 131, 345-352. 
Eskeland, R., Leeb, M., Grimes, G.R., Kress, C., Boyle, S., Sproul, D., Gilbert, N., 
Fan, Y., Skoultchi, A.I., Wutz, A., et al. (2010). Ring1B compacts chromatin structure 
and represses gene expression independent of histone ubiquitination. Molecular cell 
38, 452-464. 
Fasolato, C., Hoth, M., and Penner, R. (1993). A GTP-dependent step in the activation 
mechanism of capacitative calcium influx. The Journal of biological chemistry 268, 
20737-20740. 
Faust, C., Schumacher, A., Holdener, B., and Magnuson, T. (1995). The eed mutation 
disrupts anterior mesoderm production in mice. Development 121, 273-285. 
Fischle, W., Tseng, B.S., Dormann, H.L., Ueberheide, B.M., Garcia, B.A., 
Shabanowitz, J., Hunt, D.F., Funabiki, H., and Allis, C.D. (2005). Regulation of HP1-
chromatin binding by histone H3 methylation and phosphorylation. Nature 438, 1116-
1122. 
Fischle, W., Wang, Y., and Allis, C.D. (2003). Binary switches and modification 
cassettes in histone biology and beyond. Nature 425, 475-479. 
Gil, D., Schamel, W.W., Montoya, M., Sanchez-Madrid, F., and Alarcon, B. (2002). 
Recruitment of Nck by CD3 epsilon reveals a ligand-induced conformational change 
essential for T cell receptor signaling and synapse formation. Cell 109, 901-912. 
Gunawan, M., Venkatesan, N., Loh, J.T., Wong, J.F., Berger, H., Neo, W.H., Li, L.Y., 
La Win, M.K., Yau, Y.H., Guo, T., et al. (2015). The methyltransferase Ezh2 controls 
cell adhesion and migration through direct methylation of the extranuclear regulatory 
protein talin. Nature immunology 16, 505-516. 
126 	  
Hartsough, E.J., Meyer, R.D., Chitalia, V., Jiang, Y., Marquez, V.E., Zhdanova, I.V., 
Weinberg, J., Costello, C.E., and Rahimi, N. (2013). Lysine methylation promotes 
VEGFR-2 activation and angiogenesis. Science signaling 6, ra104. 
He, A., Shen, X., Ma, Q., Cao, J., von Gise, A., Zhou, P., Wang, G., Marquez, V.E., 
Orkin, S.H., and Pu, W.T. (2012). PRC2 directly methylates GATA4 and represses its 
transcriptional activity. Genes & development 26, 37-42. 
Hirota, T., Lipp, J.J., Toh, B.H., and Peters, J.M. (2005). Histone H3 serine 10 
phosphorylation by Aurora B causes HP1 dissociation from heterochromatin. Nature 
438, 1176-1180. 
Hobert, O., Jallal, B., and Ullrich, A. (1996). Interaction of Vav with ENX-1, a 
putative transcriptional regulator of homeobox gene expression. Molecular and 
cellular biology 16, 3066-3073. 
Hodge, C., Liao, J., Stofega, M., Guan, K., Carter-Su, C., and Schwartz, J. (1998). 
Growth hormone stimulates phosphorylation and activation of elk-1 and expression of 
c-fos, egr-1, and junB through activation of extracellular signal-regulated kinases 1 
and 2. The Journal of biological chemistry 273, 31327-31336. 
Hogan, P.G., Chen, L., Nardone, J., and Rao, A. (2003). Transcriptional regulation by 
calcium, calcineurin, and NFAT. Genes & development 17, 2205-2232. 
Huang, J., Perez-Burgos, L., Placek, B.J., Sengupta, R., Richter, M., Dorsey, J.A., 
Kubicek, S., Opravil, S., Jenuwein, T., and Berger, S.L. (2006). Repression of p53 
activity by Smyd2-mediated methylation. Nature 444, 629-632. 
Huang, J., Sengupta, R., Espejo, A.B., Lee, M.G., Dorsey, J.A., Richter, M., Opravil, 
S., Shiekhattar, R., Bedford, M.T., Jenuwein, T., et al. (2007). p53 is regulated by the 
lysine demethylase LSD1. Nature 449, 105-108. 
Huang, W., Alessandrini, A., Crews, C.M., and Erikson, R.L. (1993). Raf-1 forms a 
stable complex with Mek1 and activates Mek1 by serine phosphorylation. Proceedings 
of the National Academy of Sciences of the United States of America 90, 10947-
10951. 
Jain, J., Loh, C., and Rao, A. (1995). Transcriptional regulation of the IL-2 gene. 
Current opinion in immunology 7, 333-342. 
Jenuwein, T., and Allis, C.D. (2001). Translating the histone code. Science 293, 1074-
1080. 
Kamminga, L.M., Bystrykh, L.V., de Boer, A., Houwer, S., Douma, J., Weersing, E., 
Dontje, B., and de Haan, G. (2006). The Polycomb group gene Ezh2 prevents 
hematopoietic stem cell exhaustion. Blood 107, 2170-2179. 
127 	  
Kaneko, S., Li, G., Son, J., Xu, C.F., Margueron, R., Neubert, T.A., and Reinberg, D. 
(2010). Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-
regulates its binding to ncRNA. Genes & development 24, 2615-2620. 
Katzav, S., Sutherland, M., Packham, G., Yi, T., and Weiss, A. (1994). The protein 
tyrosine kinase ZAP-70 can associate with the SH2 domain of proto-Vav. The Journal 
of biological chemistry 269, 32579-32585. 
Kim, E., Kim, M., Woo, D.H., Shin, Y., Shin, J., Chang, N., Oh, Y.T., Kim, H., 
Rheey, J., Nakano, I., et al. (2013). Phosphorylation of EZH2 activates STAT3 
signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-
like cells. Cancer cell 23, 839-852. 
Kim, J.M., Rasmussen, J.P., and Rudensky, A.Y. (2007). Regulatory T cells prevent 
catastrophic autoimmunity throughout the lifespan of mice. Nature immunology 8, 
191-197. 
Kishimoto, A., Takai, Y., Mori, T., Kikkawa, U., and Nishizuka, Y. (1980). Activation 
of calcium and phospholipid-dependent protein kinase by diacylglycerol, its possible 
relation to phosphatidylinositol turnover. The Journal of biological chemistry 255, 
2273-2276. 
Konze, K.D., Ma, A., Li, F., Barsyte-Lovejoy, D., Parton, T., Macnevin, C.J., Liu, F., 
Gao, C., Huang, X.P., Kuznetsova, E., et al. (2013). An orally bioavailable chemical 
probe of the Lysine Methyltransferases EZH2 and EZH1. ACS chemical biology 8, 
1324-1334. 
Kornberg, R.D. (1974). Chromatin structure: a repeating unit of histones and DNA. 
Science 184, 868-871. 
Kouzarides, T. (2007). Chromatin modifications and their function. Cell 128, 693-705. 
Koyanagi, M., Baguet, A., Martens, J., Margueron, R., Jenuwein, T., and Bix, M. 
(2005). EZH2 and histone 3 trimethyl lysine 27 associated with Il4 and Il13 gene 
silencing in Th1 cells. The Journal of biological chemistry 280, 31470-31477. 
Kurash, J.K., Lei, H., Shen, Q., Marston, W.L., Granda, B.W., Fan, H., Wall, D., Li, 
E., and Gaudet, F. (2008). Methylation of p53 by Set7/9 mediates p53 acetylation and 
activity in vivo. Molecular cell 29, 392-400. 
Lee, J.M., Lee, J.S., Kim, H., Kim, K., Park, H., Kim, J.Y., Lee, S.H., Kim, I.S., Kim, 
J., Lee, M., et al. (2012). EZH2 generates a methyl degron that is recognized by the 
DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex. Molecular cell 48, 572-586. 
Lee, T.I., Johnstone, S.E., and Young, R.A. (2006). Chromatin immunoprecipitation 
and microarray-based analysis of protein location. Nature protocols 1, 729-748. 
128 	  
Lettau, M., Pieper, J., Gerneth, A., Lengl-Janssen, B., Voss, M., Linkermann, A., 
Schmidt, H., Gelhaus, C., Leippe, M., Kabelitz, D., et al. (2010). The adapter protein 
Nck: role of individual SH3 and SH2 binding modules for protein interactions in T 
lymphocytes. Protein science : a publication of the Protein Society 19, 658-669. 
Levy, D., Kuo, A.J., Chang, Y., Schaefer, U., Kitson, C., Cheung, P., Espejo, A., Zee, 
B.M., Liu, C.L., Tangsombatvisit, S., et al. (2011a). Lysine methylation of the NF-
kappaB subunit RelA by SETD6 couples activity of the histone methyltransferase 
GLP at chromatin to tonic repression of NF-kappaB signaling. Nature immunology 
12, 29-36. 
Levy, D., Liu, C.L., Yang, Z., Newman, A.M., Alizadeh, A.A., Utz, P.J., and Gozani, 
O. (2011b). A proteomic approach for the identification of novel lysine 
methyltransferase substrates. Epigenetics & chromatin 4, 19. 
Lewis, E.B. (1978). A gene complex controlling segmentation in Drosophila. Nature 
276, 565-570. 
Li, G., Margueron, R., Ku, M., Chambon, P., Bernstein, B.E., and Reinberg, D. 
(2010). Jarid2 and PRC2, partners in regulating gene expression. Genes & 
development 24, 368-380. 
Li, H., Fischle, W., Wang, W., Duncan, E.M., Liang, L., Murakami-Ishibe, S., Allis, 
C.D., and Patel, D.J. (2007). Structural basis for lower lysine methylation state-
specific readout by MBT repeats of L3MBTL1 and an engineered PHD finger. 
Molecular cell 28, 677-691. 
Li, M.M., Nilsen, A., Shi, Y., Fusser, M., Ding, Y.H., Fu, Y., Liu, B., Niu, Y., Wu, 
Y.S., Huang, C.M., et al. (2013). ALKBH4-dependent demethylation of actin 
regulates actomyosin dynamics. Nature communications 4, 1832. 
Liu, S.K., Fang, N., Koretzky, G.A., and McGlade, C.J. (1999). The hematopoietic-
specific adaptor protein gads functions in T-cell signaling via interactions with the 
SLP-76 and LAT adaptors. Current biology : CB 9, 67-75. 
Margueron, R., Justin, N., Ohno, K., Sharpe, M.L., Son, J., Drury, W.J., 3rd, Voigt, P., 
Martin, S.R., Taylor, W.R., De Marco, V., et al. (2009). Role of the polycomb protein 
EED in the propagation of repressive histone marks. Nature 461, 762-767. 
Margueron, R., Li, G., Sarma, K., Blais, A., Zavadil, J., Woodcock, C.L., Dynlacht, 
B.D., and Reinberg, D. (2008). Ezh1 and Ezh2 maintain repressive chromatin through 
different mechanisms. Molecular cell 32, 503-518. 
Maurer-Stroh, S., Dickens, N.J., Hughes-Davies, L., Kouzarides, T., Eisenhaber, F., 
and Ponting, C.P. (2003). The Tudor domain 'Royal Family': Tudor, plant Agenet, 
Chromo, PWWP and MBT domains. Trends in biochemical sciences 28, 69-74. 
129 	  
Mazur, P.K., Reynoird, N., Khatri, P., Jansen, P.W., Wilkinson, A.W., Liu, S., 
Barbash, O., Van Aller, G.S., Huddleston, M., Dhanak, D., et al. (2014). SMYD3 
links lysine methylation of MAP3K2 to Ras-driven cancer. Nature 510, 283-287. 
Monks, C.R., Kupfer, H., Tamir, I., Barlow, A., and Kupfer, A. (1997). Selective 
modulation of protein kinase C-theta during T-cell activation. Nature 385, 83-86. 
Murray, K. (1964). The Occurrence of Epsilon-N-Methyl Lysine in Histones. 
Biochemistry 3, 10-15. 
Ngoenkam, J., Paensuwan, P., Preechanukul, K., Khamsri, B., Yiemwattana, I., Beck-
Garcia, E., Minguet, S., Schamel, W.W., and Pongcharoen, S. (2014). Non-
overlapping functions of Nck1 and Nck2 adaptor proteins in T cell activation. Cell 
communication and signaling : CCS 12, 21. 
O'Carroll, D., Erhardt, S., Pagani, M., Barton, S.C., Surani, M.A., and Jenuwein, T. 
(2001). The polycomb-group gene Ezh2 is required for early mouse development. 
Molecular and cellular biology 21, 4330-4336. 
Ogawa, M., Hiraoka, Y., and Aiso, S. (2003). The Polycomb-group protein ENX-2 
interacts with ZAP-70. Immunology letters 86, 57-61. 
Paensuwan, P., Hartl, F.A., Yousefi, O.S., Ngoenkam, J., Wipa, P., Beck-Garcia, E., 
Dopfer, E.P., Khamsri, B., Sanguansermsri, D., Minguet, S., et al. (2016). Nck Binds 
to the T Cell Antigen Receptor Using Its SH3.1 and SH2 Domains in a Cooperative 
Manner, Promoting TCR Functioning. J Immunol 196, 448-458. 
Pages, G., Guerin, S., Grall, D., Bonino, F., Smith, A., Anjuere, F., Auberger, P., and 
Pouyssegur, J. (1999). Defective thymocyte maturation in p44 MAP kinase (Erk 1) 
knockout mice. Science 286, 1374-1377. 
Pasini, D., Bracken, A.P., Jensen, M.R., Lazzerini Denchi, E., and Helin, K. (2004). 
Suz12 is essential for mouse development and for EZH2 histone methyltransferase 
activity. The EMBO journal 23, 4061-4071. 
Pauker, M.H., and Barda-Saad, M. (2011). Studies of novel interactions between Nck 
and VAV SH3 domains. Communicative & integrative biology 4, 175-177. 
Pawson, T. (1994). SH2 and SH3 domains in signal transduction. Advances in cancer 
research 64, 87-110. 
Pawson, T., and Gish, G.D. (1992). SH2 and SH3 domains: from structure to function. 
Cell 71, 359-362. 
Pereira, R.M., Martinez, G.J., Engel, I., Cruz-Guilloty, F., Barboza, B.A., Tsagaratou, 
A., Lio, C.W., Berg, L.J., Lee, Y., Kronenberg, M., et al. (2014). Jarid2 is induced by 
TCR signalling and controls iNKT cell maturation. Nature communications 5, 4540. 
130 	  
Richon, V.M., Johnston, D., Sneeringer, C.J., Jin, L., Majer, C.R., Elliston, K., Jerva, 
L.F., Scott, M.P., and Copeland, R.A. (2011). Chemogenetic analysis of human 
protein methyltransferases. Chemical biology & drug design 78, 199-210. 
Roy, E., Togbe, D., Holdorf, A.D., Trubetskoy, D., Nabti, S., Kublbeck, G., Klevenz, 
A., Kopp-Schneider, A., Leithauser, F., Moller, P., et al. (2010). Nck adaptors are 
positive regulators of the size and sensitivity of the T-cell repertoire. Proceedings of 
the National Academy of Sciences of the United States of America 107, 15529-15534. 
Sampath, S.C., Marazzi, I., Yap, K.L., Sampath, S.C., Krutchinsky, A.N., 
Mecklenbrauker, I., Viale, A., Rudensky, E., Zhou, M.M., Chait, B.T., et al. (2007). 
Methylation of a histone mimic within the histone methyltransferase G9a regulates 
protein complex assembly. Molecular cell 27, 596-608. 
Santiveri, C.M., Borroto, A., Simon, L., Rico, M., Alarcon, B., and Jimenez, M.A. 
(2009). Interaction between the N-terminal SH3 domain of Nck-alpha and CD3-
epsilon-derived peptides: non-canonical and canonical recognition motifs. Biochimica 
et biophysica acta 1794, 110-117. 
Sanulli, S., Justin, N., Teissandier, A., Ancelin, K., Portoso, M., Caron, M., Michaud, 
A., Lombard, B., da Rocha, S.T., Offer, J., et al. (2015). Jarid2 Methylation via the 
PRC2 Complex Regulates H3K27me3 Deposition during Cell Differentiation. 
Molecular cell 57, 769-783. 
Schuettengruber, B., Chourrout, D., Vervoort, M., Leblanc, B., and Cavalli, G. (2007). 
Genome regulation by polycomb and trithorax proteins. Cell 128, 735-745. 
Secrist, J.P., Karnitz, L., and Abraham, R.T. (1991). T-cell antigen receptor ligation 
induces tyrosine phosphorylation of phospholipase C-gamma 1. The Journal of 
biological chemistry 266, 12135-12139. 
Seger, R., Ahn, N.G., Posada, J., Munar, E.S., Jensen, A.M., Cooper, J.A., Cobb, 
M.H., and Krebs, E.G. (1992). Purification and characterization of mitogen-activated 
protein kinase activator(s) from epidermal growth factor-stimulated A431 cells. The 
Journal of biological chemistry 267, 14373-14381. 
Shaw, J.P., Utz, P.J., Durand, D.B., Toole, J.J., Emmel, E.A., and Crabtree, G.R. 
(1988). Identification of a putative regulator of early T cell activation genes. Science 
241, 202-205. 
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J.R., Cole, P.A., Casero, R.A., 
and Shi, Y. (2004). Histone demethylation mediated by the nuclear amine oxidase 
homolog LSD1. Cell 119, 941-953. 
Strahl, B.D., and Allis, C.D. (2000). The language of covalent histone modifications. 
Nature 403, 41-45. 
131 	  
Strahl, B.D., Ohba, R., Cook, R.G., and Allis, C.D. (1999). Methylation of histone H3 
at lysine 4 is highly conserved and correlates with transcriptionally active nuclei in 
Tetrahymena. Proceedings of the National Academy of Sciences of the United States 
of America 96, 14967-14972. 
Su, I.H., Basavaraj, A., Krutchinsky, A.N., Hobert, O., Ullrich, A., Chait, B.T., and 
Tarakhovsky, A. (2003). Ezh2 controls B cell development through histone H3 
methylation and Igh rearrangement. Nature immunology 4, 124-131. 
Su, I.H., Dobenecker, M.W., Dickinson, E., Oser, M., Basavaraj, A., Marqueron, R., 
Viale, A., Reinberg, D., Wulfing, C., and Tarakhovsky, A. (2005). Polycomb group 
protein ezh2 controls actin polymerization and cell signaling. Cell 121, 425-436. 
Takenawa, T., and Suetsugu, S. (2007). The WASP-WAVE protein network: 
connecting the membrane to the cytoskeleton. Nature reviews Molecular cell biology 
8, 37-48. 
Tavares, L., Dimitrova, E., Oxley, D., Webster, J., Poot, R., Demmers, J., Bezstarosti, 
K., Taylor, S., Ura, H., Koide, H., et al. (2012). RYBP-PRC1 complexes mediate H2A 
ubiquitylation at polycomb target sites independently of PRC2 and H3K27me3. Cell 
148, 664-678. 
Tee, W.W., Shen, S.S., Oksuz, O., Narendra, V., and Reinberg, D. (2014). Erk1/2 
activity promotes chromatin features and RNAPII phosphorylation at developmental 
promoters in mouse ESCs. Cell 156, 678-690. 
Tumes, D.J., Onodera, A., Suzuki, A., Shinoda, K., Endo, Y., Iwamura, C., Hosokawa, 
H., Koseki, H., Tokoyoda, K., Suzuki, Y., et al. (2013). The polycomb protein Ezh2 
regulates differentiation and plasticity of CD4(+) T helper type 1 and type 2 cells. 
Immunity 39, 819-832. 
Tuosto, L., Michel, F., and Acuto, O. (1996). p95vav associates with tyrosine-
phosphorylated SLP-76 in antigen-stimulated T cells. The Journal of experimental 
medicine 184, 1161-1166. 
Turner, M., and Billadeau, D.D. (2002). VAV proteins as signal integrators for multi-
subunit immune-recognition receptors. Nature reviews Immunology 2, 476-486. 
Vermillion, K.L., Lidberg, K.A., and Gammill, L.S. (2014). Cytoplasmic protein 
methylation is essential for neural crest migration. The Journal of cell biology 204, 95-
109. 
Villalba, M., Bi, K., Hu, J., Altman, Y., Bushway, P., Reits, E., Neefjes, J., Baier, G., 
Abraham, R.T., and Altman, A. (2002). Translocation of PKC[theta] in T cells is 
mediated by a nonconventional, PI3-K- and Vav-dependent pathway, but does not 
absolutely require phospholipase C. The Journal of cell biology 157, 253-263. 
132 	  
Villalba, M., Coudronniere, N., Deckert, M., Teixeiro, E., Mas, P., and Altman, A. 
(2000). A novel functional interaction between Vav and PKCtheta is required for 
TCR-induced T cell activation. Immunity 12, 151-160. 
Wagner, E.J., and Carpenter, P.B. (2012). Understanding the language of Lys36 
methylation at histone H3. Nature reviews Molecular cell biology 13, 115-126. 
Wang, H., Wang, L., Erdjument-Bromage, H., Vidal, M., Tempst, P., Jones, R.S., and 
Zhang, Y. (2004). Role of histone H2A ubiquitination in Polycomb silencing. Nature 
431, 873-878. 
Weber, J.S., Kahler, K.C., and Hauschild, A. (2012). Management of immune-related 
adverse events and kinetics of response with ipilimumab. Journal of clinical oncology 
: official journal of the American Society of Clinical Oncology 30, 2691-2697. 
Weiss, A., Koretzky, G., Schatzman, R.C., and Kadlecek, T. (1991). Functional 
activation of the T-cell antigen receptor induces tyrosine phosphorylation of 
phospholipase C-gamma 1. Proceedings of the National Academy of Sciences of the 
United States of America 88, 5484-5488. 
Wu, J., Motto, D.G., Koretzky, G.A., and Weiss, A. (1996). Vav and SLP-76 interact 
and functionally cooperate in IL-2 gene activation. Immunity 4, 593-602. 
Wurm, S., Zhang, J., Guinea-Viniegra, J., Garcia, F., Munoz, J., Bakiri, L., Ezhkova, 
E., and Wagner, E.F. (2015). Terminal epidermal differentiation is regulated by the 
interaction of Fra-2/AP-1 with Ezh2 and ERK1/2. Genes & development 29, 144-156. 
Yang, S.H., Shore, P., Willingham, N., Lakey, J.H., and Sharrocks, A.D. (1999). The 
mechanism of phosphorylation-inducible activation of the ETS-domain transcription 
factor Elk-1. The EMBO journal 18, 5666-5674. 
Yang, X.P., Jiang, K., Hirahara, K., Vahedi, G., Afzali, B., Sciume, G., Bonelli, M., 
Sun, H.W., Jankovic, D., Kanno, Y., et al. (2015). EZH2 is crucial for both 
differentiation of regulatory T cells and T effector cell expansion. Scientific reports 5, 
10643. 
Yang, Z., Yik, J.H., Chen, R., He, N., Jang, M.K., Ozato, K., and Zhou, Q. (2005). 
Recruitment of P-TEFb for stimulation of transcriptional elongation by the 
bromodomain protein Brd4. Molecular cell 19, 535-545. 
Yap, K.L., and Zhou, M.M. (2010). Keeping it in the family: diverse histone 
recognition by conserved structural folds. Critical reviews in biochemistry and 
molecular biology 45, 488-505. 
Zeng, R., Cannon, J.L., Abraham, R.T., Way, M., Billadeau, D.D., Bubeck-
Wardenberg, J., and Burkhardt, J.K. (2003). SLP-76 coordinates Nck-dependent 
Wiskott-Aldrich syndrome protein recruitment with Vav-1/Cdc42-dependent Wiskott-
133 	  
Aldrich syndrome protein activation at the T cell-APC contact site. J Immunol 171, 
1360-1368. 
Zhang, W., Sloan-Lancaster, J., Kitchen, J., Trible, R.P., and Samelson, L.E. (1998). 
LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular 
activation. Cell 92, 83-92. 
Zhang, Y., Kinkel, S., Maksimovic, J., Bandala-Sanchez, E., Tanzer, M.C., Naselli, 
G., Zhang, J.G., Zhan, Y., Lew, A.M., Silke, J., et al. (2014). The polycomb repressive 
complex 2 governs life and death of peripheral T cells. Blood 124, 737-749. 
Zhao, E., Maj, T., Kryczek, I., Li, W., Wu, K., Zhao, L., Wei, S., Crespo, J., Wan, S., 
Vatan, L., et al. (2016). Cancer mediates effector T cell dysfunction by targeting 
microRNAs and EZH2 via glycolysis restriction. Nature immunology 17, 95-103. 
 
 
 
